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PREFACE 
Synapses are essential specialized units for communication between neuronal 
cells or between neuronal cells and target cells. A neuromuscular junction (NMJ) is a 
synapse built asymmetrically between a motor neuron and a skeletal muscle fiber, and it 
is associated with Schwann cells. In vertebrates, motor neurons release the 
neurotransmitter acetylcholine (ACh) at NMJs to convey signals to the muscle cells, 
which initiates a mechanism that eventually results in muscle contraction. Precisely 
orchestrated conversation among motor neurons, adjacent glial cells, and muscle fibers 
is crucial to compose coordinated NMJs. Among all the signaling molecules identified at 
NMJs, a family of growth and differentiation factors known as neuregulin1s (NRG1s) 
has been implicated to have multiple functions during neuromuscular synaptogenesis. 
However, its mode of function during NMJ development in vivo remains elusive. 
Meanwhile, the NRG1 gene encodes a spectrum of alternatively spliced products that 
have distinct expression profiles. These NRG1 isoforms play differential important roles 
in the development of both central nervous system (CNS) and peripheral nervous 
system (PNS). However, the regulatory machinery for NRG1 isoforms expression is 
mostly unknown.  
This dissertation focuses on the developmental roles of soluble NRG1 in 
regulating different aspects of the NMJ, and the regulation of NRG1 expression in motor 
neurons by neurotrophic factors and axon-target interactions. Chapter I begins with a 
necessary background of the NMJ structure and its development, the NRG1 gene and 
the structure of NRG1 isoforms. Previous studies on the roles of NRG1 signaling at 
NMJs, together with neurotrophic factor signaling and their functions in gene regulation, 
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are briefly introduced. Finally, the rationality of the dissertation project is presented. In 
Chapter II, a quantitative analysis of NMJ development in chicken embryos is described. 
From this background, evidence from studies with both genetic modulations and novel 
antagonist treatment reveal that NRG1 signaling regulates acetylcholine receptor 
(AChR) cluster density and size in the early developmental stage. In the middle stage, it 
is involved in regulating pre-synaptic synaptic vesicle transport and aggregation, while 
in the late stage, NRG1 is more involved in fine-tuning the NMJ asymmetrical structure 
and in promoting peri-synaptic Schwann cell development. In Chapter III, evidence is 
presented to suggest that isoform-specific transcription of NRG1 can be induced by 
neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), both in vivo and 
in vitro. The isoform-specific kinetics and underlying signaling pathway are investigated 
by further pharmacological studies. The contribution of potential cis-elements to the 
induction by BDNF is studied as well. In Chapter IV, discussion is provided, together 
with the significance of the novel understanding in the context of both normal 
development and a variety of neuromuscular disorders.  
 NRG1 plays multiple important roles in NMJ development and maintenance. 
Expression of NRG1 is also regulated by neurotrophic factor signaling both 
transcriptionally and post-translationally.  Understanding distinct functions of NRG1 at 
NMJs during different developmental stages not only promotes more appreciation for 
the multi-faceted signaling pathway, but also provides the possibility for the 
development of therapeutics to treat neuromuscular diseases. Exploring the regulatory 
machinery for the feedback loop between signaling molecules, like NRG1 and BDNF, is 
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of great interest due to their important roles in both the CNS and PNS, in the context of 
both normal development and neurological pathogenesis. 
  
vi 
 
TABLE OF CONTENTS 
Dedication ........................................................................................................................ ii 
Acknowledgments ........................................................................................................... iii 
Preface ............................................................................................................................ iv 
List of Figures .................................................................................................................. ix 
CHAPTER I: Introduction ................................................................................................ 1 
CHAPTER II:  Functions of neuregulin1 in neuromuscular junction development in  
 the chicken embryo  
Summary ....................................................................................................................... 26 
Materials and Methods .................................................................................................. 28 
Results .......................................................................................................................... 34 
Discussion ..................................................................................................................... 50 
CHAPTER III: Expression of neuregulin1 isoforms is regulated by neurotrophic  
  factors and axon-target interactions 
Summary ....................................................................................................................... 58 
Materials and Methods  ................................................................................................. 60 
Results .......................................................................................................................... 65 
Discussion ..................................................................................................................... 80 
CHAPTER IV: Conclusion and significance .................................................................. 85 
vii 
 
References  ................................................................................................................... 96 
Abstract ....................................................................................................................... 122 
Autobiographical Statement ........................................................................................ 125 
  
viii 
 
LIST OF FIGURES 
Figure 01  Cellular components of a neuromuscular junction ..................................... 4 
Figure 02.  Molecular structure of neuregulin1 isoform .............................................. 12 
Figure 03.  Neuregulin1 and ErbB receptors .............................................................. 15 
Figure 04.  Neurotrophic factors and their receptors .................................................. 22 
Figure 05.  Simplification of Trk signaling .................................................................. 24 
Figure 06. The size of AChR clusters and the degree of pre- and post-synaptic 
apposition increase during NMJ development ......................................... 35 
Figure 07.  Peri-synaptic Schwann cell development ................................................. 36 
Figure 08.  Soluble NRG1 promotes the density of AChR clusters ............................ 39 
Figure 09.  Down-regulated NRG1 signaling decreased the size of AChR clusters  
in ALDs .................................................................................................... 42 
Figure 10.  Down-regulated NRG1 signaling affected synaptic vesicle distribution  
in ALDs .................................................................................................... 44 
Figure 11.  Down-regulated NRG1 signaling decreased pre- and post-synaptic 
apposition in PITIBs ................................................................................. 46 
Figure 12.  Down-regulated NRG1 signaling affected peri-synaptic Schwann 
cell development in PITIBs ...................................................................... 49 
Figure 13.  A stage-dependent model of NRG1 signaling function in  
NMJ development .................................................................................... 53 
Figure 14.  ProNRG1 expression in motor neurons and their axons .......................... 66 
Figure 15.  Motor neurons that fail to contact their targets express lower NRG1 
mRNA levels ............................................................................................ 67 
Figure 16.  NRG1 expression can be rescued by BDNF or GDNF after limb  
bud ablation ............................................................................................. 69 
ix 
 
x 
 
Figure 17.  Differential regulation of NRG1 isoform mRNA levels by neurotrophic  
factors in rat embryonic ventral spinal cord cultures ................................ 71 
Figure 18.  Trk receptor, MEK, and PI3K inhibitors block the effect of BDNF on  
NRG1 mRNA ........................................................................................... 73 
Figure 19.  BDNF promotes transcription but has no effect on mRNA stability .......... 75 
Figure 20.  The 5’-flanking region of type I NRG1 is sufficient for BDNF induction  
of transcription ......................................................................................... 76 
Figure 21.  Protein synthesis is required for the down-regulation of NRG1 mRNA  
after BDNF-induced stimulation ............................................................... 78 
 
 
  
1 
 
CHAPTER I  
INTRODUCTION 
A history of the NMJ  
In the nervous system, information is propagated in networks of proper neuronal 
connections. A neuromuscular junction (NMJ) is the essential specialized unit for 
communication between a motor neuron, a target muscle cell, and surrounding 
Schwann cells. The study of the NMJ can be traced back to the birth of neuroscience. It 
has been utilized to illustrate synaptogenesis for the last century due to its large size, 
accessibility, and simplicity. Santiago Ramón y Cajal, the winner of the Nobel Prize in 
Physiology or Medicine in 1906, described some main structural features of 
neuromuscular synaptogenesis and regeneration (Ramón y Cajal, 1928). The first 
detailed description of chemical synaptic transmission in vertebrate skeletal NMJs was 
published by Henry Dale (Dale et al., 1936), who won the Nobel Prize in Physiology or 
Medicine in 1936, for discoveries relating to chemical transmission of nerve impulses. 
With the development of techniques like intracellular recording and electron microscopy 
during the 1950s, Bernard Katz and colleagues showed that the release of the 
neurotransmitter, acetylcholine (ACh) at the NMJ, is quantal and vesicular (Katz, 1966). 
Katz won the Nobel Prize in Physiology or Medicine for his discovery in 1970. With 
these descriptive studies as the foundation for experimental analysis, orchestrated 
signaling between nerve and muscle began to be appreciated (Dennis, 1981). Several 
candidate signaling molecules were isolated, and their bioactivities were demonstrated 
in vitro (Hall and Sanes, 1993).  In the era of advanced imaging, molecular biology, and 
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animal genetic tools, genes coding for structural components of the NMJ and signaling 
molecules that mediate the interaction were molecularly cloned.  The critical hypotheses 
generated from the previous studies were tested in vivo (Sanes et al., 1998). This rich 
history has given us an enormous understanding of the NMJ architecture, development, 
and function. Some of the fundamental mechanisms and signaling molecules identified 
at NMJs are shared by synaptogenesis in the central nervous system as well (Lai and 
Ip, 2003). 
 
The architecture of the NMJ 
The vertebrate NMJ is composed of the distal portion of a motor neuron axon, a 
muscle cell, and peri-synaptic Schwann cells. To fulfill the task of generating an 
appropriate muscle contraction by the chemical transmission of the electrical impulses 
from the nerve to the muscle, these three cell types are specialized at the junctional part 
with the restricted subcellular distribution of arrays of molecules, resulting in a 
structurally distinctive and functional NMJ. The pre-synaptic motor axon terminals have 
the apparatus featured to release neurotransmitter at high efficacy. Arrays of synaptic 
vesicles containing ACh dock at the thickened pre-synaptic membrane patches, referred 
as active zones, where the vesicles fuse with the membrane to release 
neurotransmitters. A large number of mitochondria accumulate at the nerve terminal to 
provide energy for ACh synthesis and release. On the other hand, cytoskeleton 
structures such as microtubules and neurofilaments are restricted in the pre-synaptic 
terminal to provide space for the mass of vesicles. Some voltage-dependent potassium 
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and calcium channels are associated with the active zone to facilitate the calcium-
dependent neurotransmitter release. The post-synaptic fraction of the muscle fiber is 
specialized to respond efficiently and rapidly to the neurotransmitter from the overlying 
nerve terminal. The post-synaptic membrane is enriched with acetylcholine receptors 
(AChRs) opposite the active zone, the density of which (>10,000 receptors/µm2) is 
extremely high compared to the non-synaptic area (~10 receptors/µm2 in adults). 
 The post-synaptic membrane invaginates to form junctional folds beneath the 
nerve terminal. AChRs are concentrated at the crests and upper parts of these folds. On 
the vertebrate skeletal muscle fiber, ACh binds to the AChRs to open the ligand-gated 
sodium channels, allowing sodium influx to initiate muscle contraction. Peri-synaptic 
Schwann cells extend processes to wrap the axon terminal. In frogs and rodents, a 
typical adult NMJ is associated with three to four peri-synaptic Schwann cells. Unlike 
the axon-associated Schwann cells, peri-synaptic Schwann cells are specialized not to 
form a myelin sheath, but to act as a physical barrier to insulate the junction structure 
from environmental perturbations. A synaptic cleft separates the pre- and post-synaptic 
components of the NMJ, spanning ~50 nm with the basal lamina, a highly specialized 
extracellular matrix (ECM) made up of a number of molecules. The ECM is comprised 
of arrays of laminin, collagen, heparan sulfate proteoglycan (HSPG), and 
acetylcholinesterase (AChE), to facilitate cell adhesion and signaling processes. The 
short distance of the synaptic cleft in combination with the high concentrations of 
neurotransmitter promote the rapid diffusion of ACh to the opposite post-synaptic 
muscle membrane. AChE that is anchored on the lamina degrades acetylcholine into 
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acetate and choline to terminate the signal efficiently and to halt the nerve impulse. The 
architecture of a vertebrate NMJ is illustrated in Fig. 1. 
 
Figure1. Cellular components of a neuromuscular junction. The NMJ consists of a 
pre-synaptic motor neuron, a post-synaptic muscle fiber, and peri-synaptic Schwann 
cells. A layer of extracellular matrix separates the pre- and post-synaptic components. 
The post-synaptic membrane is organized into junctional folds. The action potential is 
propagated along the motor axon to the pre-synaptic nerve terminal. The calcium influx 
triggers the release of acetylcholine (ACh) from synaptic vesicles at active zones. ACh 
binds to the acetylcholine receptors (AChRs) concentrated on the crests of the 
junctional folds. Post-synaptic membrane depolarization results in the muscle fiber 
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action potential. Subsequently, ACh diffuses away from the receptors and undergoes 
breakdown by acetylcholinesterase (AChE). Peri-synaptic Schwann cells insulate the 
junctional structure. Sub-synaptic nuclei in muscle fibers underlying pre-synaptic motor 
axon endings are specialized in the transcriptional programs of proteins enriched at the 
NMJ. Adapted from (Sanes and Lichtman, 1999a). 
 
Development of the NMJ 
Along with Schwann cells, motor axon trunks arrive at peripheral regions of 
developing muscles shortly before the primary myotubes are differentiated. Later on, 
primary intramuscular branches diverge from the nerve trunk to enter the muscle mass 
vertically to the proximodistal axis of the myotubes. Secondary and tertiary ramifications 
are subsequently formed to innervate the skeletal muscle fibers. When motor terminals 
contact muscle fibers, pre-synaptic components are accumulated in the terminal 
apparatus, which results in morphological changes. Distinct types of muscle-derived 
organizing factors coordinate the NMJ formation, maturation, and maintenance by 
promoting nerve terminal differentiation. It has been shown that members of the 
fibroblast growth factor (FGF) family and extracellular matrix proteins such as laminins 
and collagens control discrete sequential aspects of pre-synaptic apparatus 
development. The expression profiles of these target-derived proteins spatiotemporally 
correlate with their regulatory functions (Fox et al., 2007). The bidirectional signaling 
between the signaling molecules of ephrins and their Eph family of receptor tyrosine 
kinases is involved in axon-guidance and motor neuron terminal differentiation. The 
ephrin-Eph signaling is frequently repulsive; therefore, motor axons expressing Eph are 
guided to the appropriate tissue lacking ephrin expression with surrounding 
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inappropriate tissue expressing ephrins (Marquardt et al., 2005). Disturbance of the 
expression selectivity resulted in abnormal topographic innervations and defective 
NMJs (Feng et al., 2000). Muscle-derived β-catenin has been suggested to serve as a 
retrograde signal to modulate pre-synaptic differentiation and function (Li et al., 2008). 
Taken together, multiple signaling pathways are mandatory to promote differentiation 
and positioning of pre-synaptic terminals at NMJs. 
On the post-synaptic side, prior to the arrival of nerve terminals onto the muscle 
fibers, the expression of AChR subunits is up-regulated and AChR clusters appear to be 
evenly distributed along the myotubes; these initial clusters are not in direct contact with 
the nerve profiles (Arber et al., 2002). When innervation occurs, large AChR clusters 
appear in the synaptic regions while AChR clusters in the non-synaptic regions are 
finally eliminated. Meanwhile, by the subjunctional myonuclei, a variety of genes coding 
for post-synaptic proteins, such as rapsyn and dystrophin, are expressed to aggregate 
in the small invaginated fractions of the muscle membrane. Together with these 
proteins, AChRs are highly concentrated in the post-synaptic membrane and co-register 
with active zones in the pre-synaptic terminal to ensure robust and fast synaptic 
transmission (Sanes and Lichtman, 2001). Although intensively investigated, the 
underlying mechanisms responsible for this process are not fully understood. 
Traditionally, it is believed that post-synaptic differentiation is regulated by neural inputs, 
including both motor neuron-derived growth factors and neuronal activity. Low-density 
lipoprotein receptor-related protein 4 (Lrp4) interacts with muscle-specific kinase 
(MuSK) to form a receptor complex on the post-synaptic density. Agrin, a heparan 
sulfate proteoglycan derived from motor neurons, binds to the Lrp4-MuSK complex to 
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facilitate MuSK phosphorylation and consequent kinase activation. Activated MuSK 
triggers a signaling pathway that leads to post-synaptic differentiation which includes 
AChR clustering (Kim et al., 2008, Zhang et al., 2008). ACh, the neurotransmitter at the 
vertebrate NMJ, not only mediates physiological function, but also plays a regulatory 
role in the formation of the synapses they serve. Eliminating ACh in mice lacking the 
ACh synthetic enzyme, choline acetyltransferase (ChAT), results in a markedly 
increased number of AChR clusters which occupy a broader band width on the muscle, 
suggesting that ACh negatively regulates post-synaptic differentiation (Misgeld et al., 
2002, Brandon et al., 2003). It has been proposed that agrin promotes AChR clustering, 
while ACh counteracts by destabilizing nascent post-synaptic sites, because mice 
lacking both ChAT and agrin reverse the NMJ deficits exhibited by mice lacking agrin 
alone (Misgeld et al., 2005). The balanced interactions between the neurotransmitter 
and the growth factors ensure that the NMJ forms correctly. 
Compared to the pre-synaptic nerve terminal and post-synaptic density 
differentiation, developmental processes of peri-synaptic Schwann cells have attracted 
little attention until recently. In fact, peri-synaptic Schwann cells had not been 
recognized as an integral component of the NMJ until two decades ago (Araque et al., 
1999). In the mouse, similar to myelinating Schwann cells, peri-synaptic Schwann cells 
also originate from the neural crest cells. During migration along the nerve, Schwann 
cell precursors differentiate to immature Schwann cells; subsequently, some of the 
immature Schwann cells further differentiate to non-myelinating peri-synaptic Schwann 
cells, probably depending on their association with the terminal axon and apposition to 
the junction site. In contrast to the more well-characterized axon-associated Schwann 
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cell development, the underlying mechanisms for peri-synaptic Schwann cell 
differentiation are poorly understood. Except for the roles of providing essential energy 
metabolites and maintaining the ionic balance of the extracellular environment, several 
lines of evidence have revealed that peri-synaptic Schwann cells actively interact with 
both pre- and post-synaptic compartments and are important for proper information 
processing in NMJ development (Araque et al., 1999, Auld and Robitaille, 2003a, b). 
These cells detect synaptic activity at NMJs and, in turn, release signal molecules that 
modulate neurotransmission (Jahromi et al., 1992, Reist and Smith, 1992, Robitaille, 
1998, Castonguay and Robitaille, 2001).  
The wrapping of nerve terminals by immature Schwann cells tightens up during 
pre-synaptic and post-synaptic specialization (Sugiura and Lin, 2011). Additionally, the 
number of peri-synaptic Schwann cells per NMJ is associated with the size of the NMJ 
that they cover. Neurotrophin 3 (NT-3) secreted by muscles has been shown to have 
regulatory roles in determining peri-synaptic Schwann cell number (Hess et al., 2007). 
Perturbation of peri-synaptic Schwann cells leads to retraction of nerve terminals from 
NMJs and reduction of pre-synaptic function, suggesting that they play important roles 
in maintaining NMJ integrity (Trachtenberg and Thompson, 1997, Reddy et al., 2003). 
Recently, it has been suggested that a new component of the NMJ, the kranocyte, a 
fibroblast-like cell, lies outside the synaptic basal lamina and caps the peri-synaptic 
Schwann cells by extending processes over the entire end-plate. They are evenly 
distributed in the embryonic muscle, but become restricted to the NMJ during postnatal 
development. However, the presence of endothelial cells at NMJs remains debatable 
and their function in NMJ formation remains unclear (Court et al., 2008).  
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Thus, during NMJ development, reciprocal signaling between motor neurons, 
their target muscle fibers, and peri-synaptic glial cells is important for the precise 
physical apposition of the tripartite complex, which further ensures reliable functional 
neurotransmission.  Among all the different signaling molecules acting as either pro- or 
anti-synaptogenic signals, neureuglin1 (NRG1) is one of the important participants due 
to its multi-faceted function at NMJs. 
 
Neuregulin1 
The neuregulins (NRGs) are a family of growth and differentiation factors with 
important roles in heart and nervous system development, and pathogenesis of 
diseases from breast and ovarian cancers to schizophrenia (Fischbach and Rosen, 
1997, Buonanno and Fischbach, 2001, Falls, 2003, Esper et al., 2006, Mei and Xiong, 
2008). Although there are 4 NRG genes in the human genome, most research interests 
have focused on the first NRG gene discovered, NRG1, in part because it is abundant 
in the nervous system and might play a role in cancer (Carraway et al., 1997, Zhang et 
al., 1997, Harari et al., 1999, Esper et al., 2006). The nomenclature of NRG1 isoforms is 
originally based on their biological activities when they were first discovered 
independently, such as acetylcholine receptor inducing activity (ARIA), glial growth 
factor (GGF), sensory and motor neuron derived factor (SMDF), neu differentiation 
factor (NDF), and heregulin. Later, it was revealed that the single NRG1 gene gives rise 
to at least 33 different isoforms and several long non-coding RNAs (lncRNAs) through a 
combination of usage of different regulatory regions and alternative splicing (Meyer and 
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Birchmeier, 1995, Falls, 2003, Steinthorsdottir et al., 2004, Tan et al., 2007, Mei and 
Xiong, 2008, Rosenbloom et al., 2013).  
Most NRG1 isoforms are synthesized as transmembrane precursors (proNRG1s) 
and are processed by proteolytic cleavage at a juxtamembrane region mediated by 
various transmembrane proteases, including a disintegrin and metalloproteinase 10 
(ADAM10), tumor necrosis factor-α converting enzyme (TACE/ADAM17), β-site of 
amyloid precursor protein cleaving enzyme (BACE), and meltrin beta (ADAM19) (Loeb 
et al., 1998, Shirakabe et al., 2001, Horiuchi et al., 2005, Hu et al., 2006, Willem et al., 
2006, Montero et al., 2007, Yokozeki et al., 2007, La Marca et al., 2011, Luo et al., 
2011). The common feature of all known NRG1 is an EGF-like domain that is necessary 
and sufficient for binding and activating their tyrosine kinase receptors, including homo- 
and hetero-dimers of ErbB2, ErbB3 and ErbB4 as shown in Fig. 3 (Loeb and Fischbach, 
1995, Buonanno and Fischbach, 2001, Citri et al., 2003). Based on their domain 
structure, NRG1 isoforms can be categorized into six types (I-VI) which can be further 
divided into two groups. A majority of the soluble forms of NRG1 have been found to 
have a heparin binding, immunoglobulin-like domain N terminal to the EGF-like domain, 
referred to HBD-NRG1 (type I/II/IV/V) (Loeb and Fischbach, 1995, Mei and Xiong, 
2008). This type of NRG1 releases its ectodomain through a protein kinase C-δ (PKC-δ) 
mediated cleavage (Esper and Loeb, 2009). CRD-NRG1 (type III) has a cysteine-rich 
domain that can keep it membrane-tethered after processing so that it mainly works 
through direct cell-cell interactions as shown in Fig. 2 (Ho et al., 1995, Yang et al., 1998, 
Wang and Scott, 2000, Wolpowitz et al., 2000). Type V NRG1 lacks the HBD but has a 
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unique N-terminal domain, the function of which is less understood (Mei and Xiong, 
2008).  
This dissertation will mainly focus on types I-III, because they are the most 
abundant isoforms in the nervous system (Liu et al., 2011).  Although these NRG1 
isoforms share complimentary activities in signaling, they have significant differences in 
both post-translational processing and temporal-spatial specific expression profiles, 
which are precisely regulated by intercellular communication and neuronal activity 
(Meyer et al., 1997, Eilam et al., 1998, Liu et al., 2011). It will be important to 
understand their specific functions, both independently and jointly, and where they 
function along different regions of the same motor axon during the development of 
NMJs. 
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Figure2. Molecular structure of neureuglin1 isoforms. A. The NRG1 gene encodes 
over 30 protein isoforms, which are classified into six types based on the N-terminal 
sequences. The most abundant forms in the nervous system are type I, II, and III. All 
types of NRG1 isoforms share an epidermal growth factor (EGF)-like domain. Types I/II 
have an immunoglobulin (Ig)-like heparin-binding domain (HBD) before the EGF-like 
domain, either with or without the spacer region (S).  Type III contains a cysteine-rich 
domain (CRD) that is directly connected to the EGF-like domain. Variants of types of 
NRG1 isoforms are generated by alternative splicing in the linker regions and the C-
terminal regions. Main exons are indicated by boxes with typical length of the exons in 
the human genome. B. Most NRG1 isoforms are synthesized as transmembrane 
precursors (pro-NRG1s) with the EGF-like domain located in the extracellular region. 
Proteolytic shedding produces mature NRG1 proteins that are either soluble (type I/II), 
or membrane-tethered (type III). Adapted from (Mei and Xiong, 2008). 
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The putative roles of NRG1 at the NMJ  
The NRG1-ErbB ligand-receptor signaling system is perfectly positioned in NMJ 
development. NRG1 is highly expressed in spinal motor neurons and sensory ganglia 
neurons shortly after their birth and is efficiently transported along the axon to reach 
endplates (Loeb et al., 1999). ErbB receptors are highly expressed in corresponding 
targets including skin, muscle, and Schwann cells (Moscoso et al., 1995, Zhu et al., 
1995). Due to the interaction between the HBD and HSPGs, HBD-NRG1 is 
concentrated in the extracellular matrix of the synaptic cleft and provides biologically 
important, sustained activation of ErbB receptors on muscle cells and peri-synaptic 
Schwann cells (Loeb and Fischbach, 1995, Meier et al., 1998, Loeb et al., 1999, 
Trinidad et al., 2000, Li and Loeb, 2001). In contrast, the function of CRD-NRG1 is 
confined between cellular components within a short distance, such as motor axons and 
myelinating Schwann cells, because the molecule remains membrane-tethered after 
proteolysis (Michailov et al., 2004, Taveggia et al., 2005, Nave and Salzer, 2006). The 
signaling from activated ErbB receptors can be conveyed through a number of 
pathways, including Ras-Extracellular signal regulated kinase 1/2 (Erk1/2), 
phosphatidylinositol-3-Kinase (PI3K)-Akt, c-JUN N-terminal kinase (JNK), focal 
adhesion kinase (FAK), and Calcineurin/NFAT, depending on the cellular environmental 
contexts (Si et al., 1996, Tansey et al., 1996, Altiok et al., 1997, Si et al., 1999, 
Vartanian et al., 2000, Yarden and Sliwkowski, 2001, Kao et al., 2009). Activation of 
these pathways initiates, alone or in concert, cellular responses, such as survival, 
proliferation, differentiation, and migration, in muscle targets or Schwann cells, as 
shown in Fig. 3. In muscle cells, NRG1 signaling elicits increased expression and 
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phosphorylation of particular E-twenty six (ETS) family transcription factors, such as 
Ets-2 and GA-binding protein (GABP)-α, that bind to an N-box on the promoter of 
CHRNE, which encodes an AChR ɛ subunit, to promote transcription (Sapru et al., 
1998, Schaeffer et al., 1998, Sapru, 2001, Schaeffer et al., 2001). Besides the AChR ɛ 
subunit, several other post-synaptic components such as AChE and utrophin possess 
an N-box in their corresponding promoter regions, whose expression is also regulated 
by Ets transcriptional factors (de Kerchove D'Exaerde et al., 2002). 
  
 
15 
 
 
Figure3. Neuregulin1 and ErbB receptors. ErbB receptors are a family of 
transmembrane receptor tyrosine kinases. NRG1 binds to either ErbB3 or ErbB4. ErbB3 
has an impaired tyrosine kinase domain (red box) while ErbB2 has a non-functional 
ligand binding site (grey box). NRG1 stimulation leads to receptor dimerization to form 
ErbB2-ErbB3 or ErbB2-ErbB4 heterodimers, or ErbB4-ErbB4 homodimers. 
Phosphorylation of the intracellular kinase domains (green box) activates downstream 
signaling. The heparin-binding domain (HBD) on the soluble NRG1 (type I/II) guides the 
molecule to be concentrated in the extracellular matrix by interacting with heparan 
sulfate proteoglycans (HSPGs). Type III NRG1 functions in a manner that requires cell 
contact because the cysteine-rich domain (CRD) anchors the molecule after proteolytic 
cleavage. In the peripheral nervous system, NRG1-ErbB signaling regulates 
acetylcholine receptor (AChR) expression and local insertion, and Schwann cell 
development. Adapted from (Esper et al., 2006). 
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Although in vitro studies have shown that NRG1 can induce the local insertion of 
new AChRs into the cell surface and can increase AChR ɛ subunit transcription to 
promote the transition from embryonic to adult forms of AChRs (Jessell et al., 1979, 
Falls et al., 1993), in vivo studies using mouse genetic models thus far have not shown 
a clear requirement for NRG1 signaling at NMJs. Mice with disruptions in either all 
NRG1 forms, the HBD forms, or the NRG1 receptors ErbB2 or ErbB4, die of cardiac 
defects well before the NMJ formation, while mice with disruptions of ErbB3, the CRD-
NRG1 form, or mice that are rescued from their cardiac defects, survive until birth or die 
shortly thereafter due to a massive reduction in the number of Schwann cells in the 
peripheral nerve with the subsequent death of most motor and sensory neurons. In 
almost all cases except the CRD-NRG1 knockout mice, early embryonic NMJs appear 
grossly normal (Gassmann et al., 1995, Lee et al., 1995, Meyer and Birchmeier, 1995, 
Kramer et al., 1996, Erickson et al., 1997, Riethmacher et al., 1997, Britsch et al., 1998, 
Liu et al., 1998, Morris et al., 1999, Wolpowitz et al., 2000), while in CRD-NRG1 
knockout mice, the loss of NMJs after the initial stage probably results from sensory 
nerve and motor nerve withdrawal after Schwann cells fail to develop (Wolpowitz et al., 
2000). These limitations to studying mature NMJs have been partially overcome by 
measurements of the physiology and structure of NMJs from mice with a specific 
disruption of NRG1 signaling through the selective knockouts of NRG1 or its receptors 
in Schwann cells, motor neurons, and muscles (Escher et al., 2005, Jaworski and 
Burden, 2006, Kummer et al., 2006, Ponomareva et al., 2006). However, there are no 
major anatomical or functional deficits in the NMJ formation of any of these mice, 
indicating that NRG1 signaling does not have essential roles at NMJs in vivo despite its 
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presence. Nonetheless, consistent with the in vitro studies, HBD-NRG1 heterozygous 
mice have a 50% reduction in the AChR density on the post-synaptic membrane and a 
reduced safety factor for neuromuscular transmission, but the deficiency has been 
compensated by an increase of quantal content, suggesting that NRG1 can modulate 
the local density of AChRs (Sandrock et al., 1997, Mann et al., 2006). Selective 
knockout of ErbB2 and ErbB4 in muscle similarly show a reduction, though more 
moderate, in AChR density at NMJs (Jaworski and Burden, 2006). However, it has been 
reported that NRG1 signaling is involved in regulating the stability of post-synaptic 
AChRs at the mature NMJ by phosphorylation of α-dystrobrevin1 (Schmidt et al., 2011). 
For embryonic NMJ development, NRG1 can increase the size of AChR clusters by 
increasing the tyrosine phosphorylation of MuSK to potentiate AChR clustering  (Ngo et 
al., 2012). 
The interaction between axon-derived NRG1 and ErbB2/3 expressed on 
Schwann cell precursors, immature Schwann cells, and Schwann cells, is well 
appreciated, but roles of the signaling in the differentiation of peri-synaptic Schwann 
cells at NMJs are not as well understood (Nave and Salzer, 2006, Birchmeier and Nave, 
2008, Ma et al., 2011). Several lines of evidence suggest that NRG1 signaling is 
important for peri-synaptic Schwann cell development. Neuron-derived NRG1 is 
required for peri-synaptic Schwann cell survival during embryonic development and 
becomes dispensable in adults (Trachtenberg and Thompson, 1996). Unregulated 
NRG1 signaling by either exogenous NRG1 protein application or ectopic expression of 
activated ErbB2 in Schwann cells causes excessive sprouting and migration of peri-
synaptic Schwann cells, which mimics their response to muscle denervation and 
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subsequent reinnervation (Trachtenberg and Thompson, 1997, Hayworth et al., 2006). 
The data suggest that NRG1 signaling is critical for the development, maturation, and 
maintenance of this subpopulation of Schwann cells. However, the underlying 
mechanisms remain unknown. 
Therefore, most of the data to date in mouse models suggest that while NRG1 is 
not required to build an NMJ, it may have important modulatory roles at NMJs. 
However, fine-tuning signaling might be more valuable in the context of human 
degenerative diseases. Unlike the essential signaling such as agrin-Lrp4-MuSK, the 
deficiency of which leads to the absence of functional NMJ formation, modulatory 
signals such as NRG1-ErbB are more likely to be involved in neuromuscular 
degenerative disease pathogenesis resulting from the accumulation of subtle changes 
(DeChiara et al., 1996, Gautam et al., 1996). Our laboratory has demonstrated that 
neuregulin1 works synergistically with agrin to promote muscle AChR expression (Li et 
al., 2004a) and has provided in vivo evidence in the chicken embryo that NRG1 release 
at NMJs is activity dependent and plays an important role in converting synaptic activity 
to structural changes that maintain NMJs (Loeb et al., 2002). The laboratory has also 
studied the importance of HSPG interactions and has developed a novel antagonist to 
specifically block NRG1 signaling (Ma et al., 2009). Thus, I have a number of tools to 
assess more subtle effects of NRG1 signaling in distinct developmental stages during 
NMJ development.   
In summary, the exact functions of NRG1 in NMJ development need to be 
revealed. Should they prove important for normal development, the underlying 
mechanisms have the advantage of being potential treatments for diseases of the 
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nervous system that affect the neuromuscular interface such as myasthenia gravis (MG) 
and amyotrophic lateral sclerosis (ALS). 
 
Target-derived Neurotrophic Factors 
The developmental program of the peripheral nervous system, including axon 
guidance, axon-Schwann cell interaction, and the development of the NMJ, requires 
temporally- and spatially-orchestrated communication among motor neurons, 
surrounding Schwann cells, and target muscle fibers. The complex network of 
intercellular communication provides each cell type with distinct instructive cues, 
resulting in the activation of corresponding intracellular signaling pathways to support its 
survival and differentiation, which reinforce the supply of molecular cues to its 
counterparts. Motor neuron derived-NRG1 plays important roles in promoting Schwann 
cell development, muscle cell differentiation, and formation of the NMJ (Hippenmeyer et 
al., 2002, Loeb, 2003, Birchmeier and Nave, 2008). Conversely, both Schwann cells 
and target muscle cells provide arrays of growth and trophic factors to support the 
survival and function of motor neurons. Among these cues, members of neurotrophic 
factors are the best described. The classic neurotrophin family of trophic factors 
consists of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5), which are highly homologous and 
conserved. They bind to the specific tropomyosin-related kinases (Trks), which include 
TrkA, TrkB, and TrkC, with high affinity, and the p75 neurotrophin receptor (p75NTR) 
with low affinity. NGF predominantly binds to TrkA, BDNF and NT-4/5 to TrkB, and NT-3 
to TrkC. However, there is considerable crosstalk in the binding of neurotrophins to Trk 
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receptors. Each neurotrophin can interact with every member of the Trk receptor family 
under specific conditions, such as a high concentration of ligand (Huang and Reichardt, 
2001, 2003). To increase complexity, the TRKB and TRKC genes can be alternatively 
spliced into multiple isoforms, including full-length and truncated isoforms. Full-length 
receptors bear a tyrosine kinase domain, the phosphorylation of which activates the 
downstream signaling cascades, whereas the truncated isoforms that lack the tyrosine 
kinase domain function as dominant negative receptors, though other specific cellular 
functions have been proposed (Biffo et al., 1995, Yacoubian and Lo, 2000, Esteban et 
al., 2006). Besides neurotrophins, members of other families of proteins, most notably 
the glial cell–derived neurotrophic factor (GDNF) family, have been shown to be 
produced and secreted by muscle cells to regulate the survival and function of motor 
neurons as well (Moore et al., 1996, Oppenheim et al., 2000, Haase et al., 2002). 
Homodimeric GDNF activates receptor tyrosine kinase (RET) by first binding to GDNF-
family receptor-α1 (GFRα1) receptors (Airaksinen and Saarma, 2002). Together with 
members of the neuropoietic cytokine family, such as ciliary neurotrophic factors 
(CNTF), these neurotrophic factors function synergistically to promote the growth and 
development of neurons.  
It is well-established that a series of developmental events govern the 
establishment of appropriate connections between neurons and targets, in which 
neurons are overproduced and then compete for survival factors derived from targets. 
The neurotrophic theory is best understood for sensory and motor neurons in the 
peripheral nervous system (Oppenheim, 1989). The development and survival of 
sensory and motor neurons are differentially dependent upon specific neurotrophic 
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factors. Motor neurons express high levels of TrkB and require BDNF signaling 
(Koliatsos et al., 1993), NT-3 signaling is critical to early sensory neuron progenitors, 
while mature sensory neurons require NGF by elevating the expression of TrkA (Lefcort 
et al., 1996, Sharma et al., 2010). Subpopulations of sensory neurons express TrkB and 
TrkC, and thus, depend on BDNF and NT-3, respectively (Wright and Snider, 1995, 
Rifkin et al., 2000). In addition to TrkB, motor neurons also express a low level of TrkC, 
and thus respond to NT-3 (Ip et al., 2001). Both motor and sensory neurons respond to 
GDNF by expressing GFRα1 and Ret (Airaksinen and Saarma, 2002) as shown in Fig. 
4.  
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Figure4. Neurotrophic factors and their receptors. A. Nerve growth factor (NGF) 
binds and activates TrkA receptor tyrosine kinase; brain-derived neurotrophic factor 
(BDNF) and Neurotrohoin-4/5 (NT-4/5) bind TrkB. Neurotrohoin-3 (NT-3) binds TrkC 
with high affinity, but has low affinity for both TrkA and TrkB. Additionally, all 
neurotrophins bind to the p75 neurotrophin receptor (p75NTR) with low affinity. Glial cell 
line-derived neurotrophic factor (GDNF) binds to the soluble co-receptor GFRα1 and 
forms a complex with RET to convey the signal into the cell. B. In the peripheral 
nervous system, target cells, including muscle fibers and skin cells, provide a variety of 
neurotrophic factors to motor neurons residing in the spinal cord and sensory neurons in 
the dorsal root ganglion, to support their survival and differentiation.  Accordingly, both 
neuronal types express types of Trk receptors and GFRα1 differentially. Adapted from 
(Segal, 2003, Harrington and Ginty, 2013). 
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The binding of neurotrophic factors to their receptors leads to the recruitment of 
proteins that interact with specific phosphotyrosine residues in the cytoplasmic domains. 
These interactions lead to the activation of signaling pathways, such as the Ras/MAPK, 
PI3k/Akt, and phospholipase C (PLC)-γ pathways; afterward, specific transcriptional 
factors are recruited and chromosome modifications are subsequently altered, which 
ultimately result in the expression of downstream genes that can be involved in 
neuronal survival, axonal growth, and neuronal specification. as shown in Fig. 5 (Segal, 
2003, Zweifel et al., 2005). However, the downstream targets of these neurotrophic 
factor-dependent signals and how their dynamics contribute to the cooperative 
development are not fully understood.  
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Figure5. Simplification of Trk signaling. BDNF binds and activates TrkB. Upon ligand 
binding, cytoplasmic tyrosine residues of the receptor are phosphorylated to generate 
docking sites for linker proteins, such as Shc, and PLCγ. Shc binding initiates 
downstream signaling cascades leading to activation of MAPK signaling cascade, which 
promotes neuronal differentiation; or PI3k/Akt signaling cascade, which promotes 
neuronal survival and growth. Phosphorylation and activation of PLCγ leads to 
formation of IP3 and DAG and subsequent activation of the pathways is associated with 
either Ca2+ or PKC, which promotes synaptic plasticity. The concert of ligand, receptors, 
signal strength and duration, and neuronal types is critical to the differential activation of 
the cascades. Adapted from (Segal, 2003). 
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It has been demonstrated that some of the neurotrophic factors can not only 
induce NRG1 expression in spinal cord motor neurons (Loeb and Fischbach, 1997), but 
also promote the rapid release of soluble NRG1 from sensory and motor neurons in a 
dose-dependent manner through PKC-δ activation (Esper and Loeb, 2004, 2009). 
Regulation of neuron-derived NRG1 expression and processing by glial cell-derived 
neurotrophic factors resembles a reciprocal, positive feedback loop to promote the 
survival and differentiation of Schwann cells (Ma et al., 2011). Similarly, at NMJs, it has 
been shown that NRG1 expression is regulated by neuromuscular activity and is 
promoted by neurotrophic factors (Loeb et al., 2002). However, little is known about the 
composition of NRG1 isoforms regulated by the neurotrophic factors signals in both 
scenarios. Together, it raises the possibility of the presence of a bi-directional 
mechanism mediated by neuron-derived NRG1 and target-derived neurotrophic factors 
at NMJs, where neurotrophic factors regulate NRG1 isoform expression to provide 
various types of NRG1 as growth and differentiation factors to the adjacent cells. 
Here, I propose that the expression of different isoforms of NRG1 can be 
regulated by neurotrophic factors and axon-target interactions. The complexity of NRG1 
isoform-specific regulatory machinery in response to neurotrophic factors may 
contribute not only to the bidirectional communication between motor neurons and 
muscle targets, but also to the dynamic functions of NRG1 in other regions in the 
nervous system and pathological conditions in various diseases. 
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CHAPTER II 
FUNCTIONS OF NRG1 IN NEUROMUSCULAR JUNCTION DEVELOPMENT IN THE 
CHICKEN EMBRYO  
Summary 
The development of the neuromuscular junction (NMJ) is a multistep process 
mediated by coordinated interactions between axon terminals, target muscles, and peri-
synaptic glial cells, and therefore requires reciprocal signals derived from every cell 
type. Neuregulin1s (NRG1s) are a group of growth and differentiation factors that are 
important for many aspects of nervous system development. While NRG1 is potent in 
inducing acetylcholine receptor (AChR) transcription and clustering in vitro, whether it 
plays any regulatory roles at NMJs in vivo remains controversial. Using the chicken 
model, we developed methods to study the effects of NRG1 signaling on NMJ 
development in ovo using sequential, quantitative measures of NMJ formation including 
AChR cluster size and density, pre- and post-synaptic apposition, and the alignment of 
peri-synaptic Schwann cells. We show that over-expression of soluble NRG1 increased 
AChR cluster density, but not size, in the early developmental stage, whereas blocking 
NRG1 activity with a targeted antagonist had little effect.  In the middle stage, the NRG1 
antagonist led to moderate reduction of AChR cluster size in a temporal-specific and 
muscle type-dependent fashion. The NRG1 antagonist resulted in an altered distribution 
of synaptic vesicles, suggesting that NRG1 plays roles in directing pre-synaptic 
apparatus assembly. In the late stage, pre- and post-synaptic apposition and peri-
synaptic Schwann cell alignment were affected slightly when the antagonist was 
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applied. These findings suggest that, while not critical for development, NRG1 signaling 
can have important roles in fine-tuning multiple stages of NMJ development.  
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Materials and Methods  
Chicken eggs and in ovo treatment 
Fertilized chicken eggs were obtained from Michigan State University Poultry Farms 
and incubated in a Kuhl rocking incubator at 50% humidity. Daily treatment of the NRG1 
antagonist (HBD-S-H4) on chick embryos was performed as described previously (Loeb 
et al., 2002, Winseck et al., 2002, Ma et al., 2009, Ma et al., 2011). In brief, 20 μg of 
HBD-S-H4 was prepared in saline containing 0.2% BSA and added onto the 
chorioallantoic membrane through a small hole in the air sac without damaging 
underlying blood vessels; this was done for two consecutive days. HBD-S-H4 was 
prepared, purified, and tested for its ability to block NRG1 activity as described (Ma et 
al., 2011). Staging of chicken embryos was determined according to Hamburger-
Hamilton (HH) stage series (Hamburger and Hamilton, 1951); E2.5 (Stage 15-16); E7 
(stage 30-31); E8 (stage 34); E10 (stage 36); E12 (stage 38); E14 (stage 40); E16 
(stage 42); E18 (stage 44). 
In ovo electroporation 
Chick type I proNRG1β1a cDNA with a c-Myc tag at the C terminus was subcloned into 
the pMES vector downstream from the chick β-actin promoter with IRES–EGFP (Krull, 
2004). Similarly, a c-Myc tag was added at the C terminus of the coding sequence of 
HBD-S-H4, which was subsequently subcloned into the pMES vector. The pCAX vector 
expressing EGFP was used for coelectroporation with other plasmids to visualize 
electroporated cells (George et al., 2007). The final concentration of each plasmid was 
3 μg/μl. The plasmid DNAs were electroporated unilaterally into the ventral part of the 
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neural tube at the lumbar level at E2.5 as described previously (Ma et al., 2009). 
Electrodes were placed ventrodorsal across the neural tube and pulsed for five times at 
35 V for 50 ms with a square-wave pulse generator (Intracept TSS10; Intracel). 
Embryos were collected at time indicated, and only those with strong GFP expression 
were processed for additional analysis. 
In situ hybridization 
Chicken embryos were fixed in 4% paraformaldehyde in PBS at 4°C overnight, washed 
in PBS, equilibrated in 30% sucrose, and mounted in OCT (Tissue-Tek). Frozen 
sections were cut transversely at 14 μm and placed on Superfrost plus slides (VWR). 
Non-radioactive in situ hybridization was performed using Digoxigenin (Dig)-labeled 
RNA probes. In brief, sense and antisense Dig-labeled RNA probes were generated 
from linearized plasmid containing chicken NRG1 heparin binding domain, by in 
vitro transcription (Roche). Probes were hydrolyzed to optimum length of ~250 bp, and 
then purified on Sephadex G-50 quick spin columns for RNA purification (Roche). 
Sections were treated for 10 min at room temperature with 1 μg/ml proteinase K 
(Sigma) and acetylated with 0.25% acetic anhydride in 0.1 M triethanolamine, pH 8.0 for 
15 min. After this, the sections were incubated with 2 μg/ml probes in hybridization 
buffer at 60°C overnight. Hybridization buffer contained 50% formamide, 0.3 M NaCl, 
0.5 mg/ml yeast tRNA, 1x Denhardt's solution (Sigma), 20 mM Tris, pH 7.4, 10% 
Dextran Sulphate, 10 mM NaPO4 and 5 mM EDTA. After hybridization, the sections 
were sequentially washed in 5x SSC, 50% formamide in 1x SSC, 2x SSC, and 0.2x 
SSC for 10, 30, 20, and 20 min at 65°C. To remove excessive cRNA hybrids, the 
sections were incubated with 20 μg/ml RNase A (Sigma) in TNE buffer (10 mM Tris pH 
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7.5, 0.5 M NaCl, 1 mM EDTA), at 37°C for 30 min before they were washed by 2x SSC. 
The sections then were blocked with Blocking solution (Roche) for 1 h at room 
temperature and incubated with sheep anti-DIG conjugated with alkaline phosphatase 
(AP) (1:1000) (Roche) in blocking solution at 4°C overnight. Finally, the sections were 
washed in washing buffer (Roche), incubated in detection buffer (Roche), and then 
visualized by reacting with BM purple (nitroblue-tetrazolium-chloride (NBT)/5- bromo-4-
chlor-indolyl-phosphate (BCIP) ready-to-use solution) (Roche) in the dark for 2 h.  
Immunofluorescence staining  
Muscle whole-mounts were prepared as described previously (Dahm and Landmesser, 
1988, Loeb et al., 2002). Briefly, embryos were decapitated and eviscerated. Skin and 
connective tissue were removed to expose the underlying muscles. Anterior latissimus 
dorsi (ALD) muscles were exposed and fixed in situ by fresh 4% paraformaldehyde in 
PBS for 40 min to maintain normal muscle shape. To obtain posterior iliotibialis (PITIB), 
thighs were fixed in 4% paraformaldehyde in PBS overnight and rinsed with PBS at 
room temperature; PITIBs were then dissected off all connective tissue and the sciatic 
trunk. Whole-mount staining was adapted from previously described (Dong et al., 2006). 
Briefly, muscles were incubated in 0.1 M glycine in PBS for 1 h, and rinsed with 0.5% 
Triton X-100 in PBS. After incubation in the blocking buffer (3% BSA, 5% goat serum, 
and 0.5% Triton X-100 in PBS) for 2 h at room temperature, muscles were then 
incubated with primary antibodies (SV2, 1:100; 3A10, 1:100; Developmental Studies 
Hybridoma Bank) and α-bungarotoxin conjugated with Alexa Fluor 488 (1:500, Life 
Technologies) in the blocking buffer overnight at 4°C. After washing three times for 1 h 
each in 0.5% Triton X-100 in PBS, the muscles were incubated with goat-anti-mouse 
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IgG conjugated with Alexa Fluor 546 (1:500, Life Technologies) for 2 h at room 
temperature. After three times washed for 1 h each in 0.5% Triton X-100 in PBS, 
muscles were rinsed with PBS, and flat-mounted in mounting medium.  
For ALD after E14 and PITIB, muscles were mounted into OCT and sectioned into 20 
μm sections. Frozen embryo sections were the same as used for in situ hybridization. 
After incubation with blocking solution (10% goat serum, 0.1% Triton X-100 in PBS) at 
room temperature for 1 h, sections were incubated with α-bungarotoxin conjugated with 
Alexa Fluor 488 (1:500) and primary antibodies in blocking solution overnight at 4°C, 
followed by incubation with the corresponding goat anti-mouse or goat anti-rabbit IgG 
conjugated with Alexa Fluor antibodies for visualization. Primary antibodies were used 
at the following dilutions: Iselt1/2 (1:10, 39.4D5), P0 (1:5; 1E8), SV2 (1:100, SV2), c-
Myc (1:100, 9E10) and neurofilament (1:10; 3A10) (Developmental Studies Hybridoma 
Bank); GFP (1:100; ab6662, Abcam).  
Imaging and quantitative analysis 
Confocal stacks of images of whole mount muscle staining were acquired with a z-step 
of 1.05 µm using a Nikon Eclipse microscope with a D-Eclipse C1 confocal system. 
Twenty consecutive images were combined into a single image processed by 
MetaMorph image analysis software (Molecular Devices) using Maximum-Stack 
Arithmetic. Epifluorescent images were obtained with a Nikon Eclipse 600 
epifluorescence microscope with a Princeton Instruments Micromax 5 MHz cooled CCD 
camera, and analyzed using MetaMorph. Briefly, the threshold was adjusted for each 
nonsaturated image. Regions of interest (ROIs) were selected as objects with a 
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nearest-neighbor filter and a size filter to α-bungarotoxin signal above threshold. The 
size and total grey value of AChR clusters were determined based on ROI 
measurement. AChR cluster size was converted from pixels into area (µm2). Ratio of 
pre-synaptic and post-synaptic apposition was determined as the percentage of area 
positive for nerve terminal SV2 within each ROI of the same scope. Similarly, ratio of 
pre-synaptic and peri-synaptic apposition was determined as the percentage of area 
positive for Schwann cell P0. Extra-synaptic synaptic vesicle signal was determined by 
subtraction of terminal SV2 positive areas that were overlapped by α-bungarotoxin 
signal, from the total signal for synaptic vesicles. Subsequently, the percentage of extra-
synaptic synaptic vesicles was calculated. To quantify the density of AChR cluster in the 
early stage, the dorsal muscle mass regions with adjacent GFP+ motor axons were 
defined as ROI. The number of AChR clusters and total grey value of each cluster were 
measured within each ROI. The density was calculated after pixel-to-area conversion.  
Statistical Analysis   
Frequency histograms were produced in Prism 5.0 (GraphPad Software Inc.). 
Numerical datasets presented in histograms were tested for statistical significance by 
means of the nonparametric, two-sided Mann-Whitney U-test. For comparison between 
groups for in ovo electroporation, statistical differences were tested using one-way 
ANOVA followed by Dunnett’s post hoc test. Unpaired two-tailed Student’s t-test was 
used for analysis between animals with and without antagonist treatment. The median 
was used to represent the measurement of each section. The mean of the median from 
3-5 sections was used to represent each animal. All data are presented as the mean ± 
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SEM with an n of at least 3 animals in each group. Statistical significance is presented 
as * p<0.05, ** p<0.01.  
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Results 
Quantitative parameters for neuromuscular junction development in the chicken 
embryo 
Although there have been a number of studies on NMJ development in the 
chicken embryo, few of them provided multiple quantitative measures along with 
development (Burden, 1977a, b, Dahm and Landmesser, 1988). Here, we developed 
three quantitative parameters to investigate NMJ development in the hindlimb posterior 
iliotibialis (PITIB) muscle, which is a focally innervated, homogeneous, fast-twitch 
muscle (Dahm and Landmesser, 1988). The first measure includes both AChR cluster 
size and density using fluorescently labeled α-bungarotoxin (BTX). The other two 
measures quantify the degree of apposition of motor nerve endings and peri-synaptic 
Schwann cells with those AChR clusters.  Fig. 6 and 7 show the developmental time 
course for each of these 3 measures from embryonic day 7 (E7) through E18. At E7, the 
majority of AChR clusters are small (median size <2 µm2) and are not yet associated 
with nerve terminals. AChR cluster size increases most significantly between E7 and 
E10 and then gradually increases further to around 15 µm2 by E18 (Fig. 6A, 6B). 
Pre- and postsynaptic apposition occurs synchronously with increased AChR 
cluster size at E10 to E12.  Between E12 and E18 pre- and post-synaptic apposition 
increases at a steady rate until most AChR clusters are fully associated with axon 
terminals (Fig. 6A, 6C).  Lastly, the peri-synaptic Schwann cells migrate into the 
maturing NMJ starting at E14 and continue to gradually engulf the NMJ through E18 
(Fig. 7A, 7B). 
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Figure6. The size of AChR clusters and the degree of pre- and post-synaptic 
apposition increase during NMJ development. A. Representative images of the 
dorsal muscle mass of the hindlimb on E7 and the PITIBs from E10 to E18 at a two-day 
interval, showing the growth of AChR clusters and the apposition of AChR clusters 
(BTX, green) and nerve terminals (SV2, red). B, C. Graphs show the normalized 
distribution (percentage of the number of observations per bin of the total number within 
the group) of the size of AChR clusters and the percentage of post-synaptic territory 
occupied by pre-synaptic motor axon endings. Data were collected from at least 200 
NMJs. Arrows indicate the median occupancy. D,  E. The medians of the two measures 
(n=6, 6, 6, 5, 4, 4 for each stage, respectively) are plotted against developmental 
stages. Scale bar: 25μm. 
 
 
Figure7. Peri-synaptic Schwann cell development. A. Representative images of the 
PITIBs from E12 to E18 at a two-day interval show the development of Schwann cells 
(P0, red) at the neuromuscular junctional area (BTX, green). B. The percentage of 
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NMJs with >25% post-synaptic territory occupied by peri-synaptic (n=4, 3, 4, 4 for each 
stage, respectively) was plotted against developmental stages. Scale bar: 25μm. 
 
Over-expression of NRG1 in motor axons increases AChR cluster density 
In the chicken hindlimb, the first appearance of AChR clusters coincides with the 
ingrowth of nerve trunks at E4. By E7, numerous AChR clusters can be observed in a 
broad region on developing muscle fibers that are still not yet in direct contact with 
nerve endings as shown in Fig. 6A. Previous studies have shown that those AChR 
clusters that form contacts with nerve terminals enlarge, while those that do not receive 
direct nerve contact are eventually eliminated (Dahm and Landmesser, 1988). We used 
in ovo electroporation to over-express soluble NRG1 isoforms in lumbar motor neurons 
at E2.5 with a full-length type I proNRG1 β1a cDNA with a c-Myc tag at the C terminus, 
to track its distribution. This plasmid was cotransfected with a plasmid expressing GFP.  
Over-expression of NRG1 was confirmed at the mRNA level by in situ hybridization and 
at the protein level using anti-c-Myc antibodies on the electroporated side (Fig. 8A). 
Compared to controls that were electroporated with the empty vector, over-expression 
of NRG1 in motor neurons resulted in a significant increase in the density of AChR 
clusters at E7. Morphometric analysis, however, did not show a change in AChR cluster 
size (Fig. 8C, 8D). This suggests that, prior to nerve AChR cluster contact, NRG1 can 
increase the total number of AChR clusters without regulating cluster size. In contrast, 
reducing NRG1 signaling using the plasmid expressing the NRG1 antagonist HBD-S-H4 
in motor neurons did not change AChR cluster density or size (Fig. 8C, 8D).  Over-
expression of HBD-S-H4 was confirmed using antibodies against the fusion protein (Fig. 
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8B). Together, these results suggest that while NRG1 is not required for cluster 
formation or cluster size regulation, the amount of NRG1 released from nerve endings 
can promote the global level and number of AChR clusters prior to nerve muscle 
contact. 
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Figure8. Soluble NRG1 promotes the density of AChR clusters.  A. In situ 
hybridization shows up-regulated soluble proNRG1 mRNA in the ventral spinal cord of 
the electroporated side but not the contralateral side. Scale bar, 50μm. Over-expression 
of c-Myc tagged proNRG1 protein was demonstrated by c-Myc expression (red) in GFP 
(green)-positive cells. B. Expression of HBD-S-H4 was detected by HBD expression 
(anti-HBD, red; ADO3, blue) in GFP (green)-positive cells. Scale bar, 25μm.  C. 
Increased AChR cluster (BTX, red) density was observed at E7 after electroporation 
with proNRG1 (GFP, green; 3A10, blue) compared with vector alone or HBD-S-H4. D. 
Data are reported as the mean ± SEM of n = 8, 10, 8 for each condition, respectively; * 
p<0.05, one-way ANOVA followed by Bonferroni’s post hoc test by comparison to 
control. No detectable change of AChR cluster size was seen in the animals with either 
proNRG1 over-expression or HBD-S-H4 expression. 
 
NRG1 signaling promotes post-synaptic AChR clustering 
The presence of NRG1 at developing NMJs starts early and lasts until NMJ 
maturation in both chickens and mice (Meyer et al., 1997, Loeb et al., 1999). To 
determine the function of NRG1 at NMJs in the different developmental phases after 
AChR clusters get into direct contact with nerve terminals, I applied NRG1 antagonist 
HBD-S-H4 in ovo to knock down NRG1 signaling. The antagonist has been shown to 
specifically target the heparan sulfate-rich surfaces to which endogenous NRG1 binds 
and to effectively block NRG1-meditated Schwann cell precursor survival and 
differentiation (Ma et al., 2009, Ma et al., 2011). The antagonist was added to 
developing embryos for two consecutive days before the NMJs were examined at every 
stage. 
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NRG1 has been postulated to increase the transcription of AChR subunit genes, 
such as AChRα and AChRɛ, from sub-synaptic muscle nuclei by activating their ErbB 
receptors (Brenner et al., 1990, Martinou et al., 1991, Chu et al., 1995, Moscoso et al., 
1995). However, the in vivo physiological roles in promoting AChR expression remain 
contentious, especially during NMJ development. To ask whether NRG1 plays roles in 
post-synaptic AChR clustering, we examined AChR cluster size in two different muscle 
groups, the PITIB and the anterior latissimus dorsi (ALD), which is a mostly multi-
innervated, slow-tonic muscle, with and without HBD-S-H4 treatment (Hess, 1967, 
Kwong and Gauthier, 1987). We found that administration of the antagonist resulted in a 
slight, yet significant reduction of AChR cluster size in E10 ALDs. Compared to the 
control group with the mean value of 13.3 μm2 (201 clusters in 4 animals), the average 
AChR cluster size in HBD-S-H4 treated animals decreased to 11.9 μm2 (177 clusters in 
4 animals) (Fig. 9A, 9B). However, the decrease of cluster size was not observed in 
ALDs of any other stages (E12-E18) or in PITIBs of any stages (E10-E18). The 
developmental-stage-dependent requirement of NRG1 suggests that the signaling 
promotes AChR clustering in the early stage, and becomes dispensable when other 
complementary mechanisms become dominant during the late stage.    
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Figure9. Down-regulated NRG1 signaling decreased the size of AChR cluster in 
ALDs. A. Representative stacked confocal images show that treatment with HBD-S-H4 
at E8 and E9 resulted in the reduction of AChR cluster (BTX, green) size in E10 ALDs. 
The same treatment at E10 and E11 did not affect the AChR cluster size at E12. Scale 
bar, 25μm. B. The histogram summarizes the normalized distribution (percentage of the 
number of observations per binned AChR cluster size of total number within the group) 
between Saline (control) and HBD-S-H4 treated embryos, and shows significant 
decrease of AChR cluster size at E10 (* p<0.05, two sided Mann-Whitney U-test), but 
not at E12 (p>0.05, two sided Mann-Whitney U-test). Quantification of AChR cluster 
size across animals (mean ± SEM) shows similar significant decrease of AChR cluster 
size only at E10 (* p<0.05, n=4 for each condition, unpaired two-tailed Student’s t-test). 
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NRG1 signaling is required in pre-synaptic differentiation  
To ask whether NRG1 plays roles in assembling the pre-synaptic apparatus, we 
examined the pre-synaptic component of NMJ in both PITIBs and ALDs. We found that, 
in the ALDs of the saline treated group, similar to normal development, synaptic 
vesicles are initially distributed throughout the axon, but become concentrated at 
synaptic sites when pre- and post-synaptic apposition consolidates. In the antagonist-
treated muscles, the apparent major branching pattern and arborization of axon terminal 
did not differ detectably (Data not shown). However, by E14, synaptic vesicles were less 
restricted to synaptic sites in treated animals than in controls. The average percentage 
of extra-synaptic to total synaptic vesicle was 46.2 ± 5.1 (n=4) for control and 69.7 ± 2.9 
(n=4) for treatment. The similar defect was observed at E16 as well. However, the 
abnormality was less striking, with the average percentage of extra-synaptic synaptic 
vesicle level increasing from 43.9 ± 1.7 (n=4) for control to 54.8 ± 4.2 (n=4) for 
treatment. In the E18 animals, the failure of clustering of synaptic vesicles to NMJ site 
was barely detectable. The corresponding mean values were 36.7 ± 3.4 (n=4) and 35.9 
± 5.3 (n=4) for controls and antagonist-treated animals, respectively (Fig. 10). The 
results suggest that NRG1 signaling is required for transporting and clustering synaptic 
vesicles to nerve terminals in a developmental-stage-dependent fashion. However, the 
stage-dependent failure of synaptic vesicle clustering was not observed in PITIB for all 
the stages, indicating that the pre-synaptic vesicle transport and clustering regulated by 
NRG1 signaling might be muscle type-specific.  
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Figure10. Down-regulated NRG1 signaling affected synaptic vesicle distribution 
in ALDs. A. Representative images show that treatment with HBD-S-H4 at E12 and 
E13, or E14 and E15 resulted in more synaptic vesicle aggregation (SV2, red) in the 
axonal area distal to junction sites (BTX, green) in ALDs at E14 or E16, respectively. 
The synaptic vesicle distribution was not affected at E18 with the antagonist treatment 
from E16 to E17. B. Quantification of the percentage of synaptic vesicles failing to 
concentrate in nerve endings over total synaptic vesicle staining shows a significant 
increase of synaptic vesicles residing in the axonal area. Data are reported as the mean 
± SEM of n=4 for both saline and HBD-S-H4 group, * p<0.05, ** p<0.01, unpaired two-
tailed Student’s t-test. Scale bar, 25μm.  
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NRG1 signaling promotes pre- and post-synaptic apposition 
The fine apposition of pre-synaptic nerve terminal and post-synaptic AChR 
cluster is required for fast and robust neurotransmission at NMJs. Pre- and post-
synaptic apposition increases steadily from E10 to E18, until most AChR clusters are 
fully associated with axon terminals (Fig. 6A, 6B). To ask whether NRG1 plays roles in 
regulating pre- and post-synaptic apposition, we examined the degree of apposition of 
pre-synaptic nerve endings and AChR clusters on PITIBs in the presence or absence of 
HBD-S-H4 treatment. The degree of association was classified into four categories: 0-
25%, 25-50%, 50-75%, and 75-100%, as the percentage of AChR cluster territory 
occupied by nerve endings. The application of the antagonist resulted in a significant 
decrease of the proportion of high degree of association (75-100%) at E18. Compared 
to the control group with the average percentage of 70.2 ± 2.3 (n=5), the contribution of 
this category decreased to 55.6 ± 7.5 (n=5). The decrease of pre- and post-synaptic 
apposition was not observed in any other stages (E10-E16), as shown in Fig. 11. The 
results suggest that NRG1 signaling is involved in fine-tuning the apposition of the pre-
synaptic nerve terminal and post-synaptic apparatus when the NMJ matures. 
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Figure11. Down-regulated NRG1 signaling decreased pre- and post-synaptic 
apposition in PITIBs. A. Representative images of the PITIBs from E10 to E18 with 
two-day interval with or without HBD-S-H4 treatment show that the antagonist applied at 
E16 and E17 resulted in less degree of post-synaptic AChR cluster (BTX, green) 
territory association with nerve terminal (SV2, red) in PITIBs at E18. B. The association 
was classified into four categories: 0-25%, 25-50%, 50-75%, and 75-100%. 
Quantification of the percentage of each category shows significant decrease of the 
proportion of the NMJs that have high degree of association (75-100%). Data are 
reported as the mean ± SEM of n=5 for saline and HBD-S-H4 group, two-way ANOVA; * 
p<0.05. The effect was not observed in all the earlier stages. C. Bottom panel shows 
zoomed-in images of the arrowed NMJ in the image of E18. Scale bar, 25μm. 
 
NRG1 signaling promotes peri-synaptic Schwann cell development 
Peri-synaptic Schwann cells wrap the junctional site of both motor axon terminals 
and post-synaptic apparatuses. This ideal location allows them to be actively involved in 
NMJ formation, maintenance of structural integrity, and signal transduction (Auld and 
Robitaille, 2003b). In contrast to axon-associated Schwann cell development, the 
underlying mechanisms for peri-synaptic Schwann cell differentiation are poorly 
understood. To determine if modulation of NRG1 signaling is involved in the 
development of the subtype of Schwann cells, we examined the alignment of Schwann 
cells and AChR clusters in the absence or presence of HBD-S-H4. The treatment with 
the antagonist significantly decreased the degree of Schwann cells apposed to AChR 
clusters at E14, E16, and E18, compared to the saline treatment. The mean value of 
percentage of AChR cluster area associated with Schwann cells decreased from 
approximately 15 with Saline to 11 with HBD-S-H4 at E14 (p<0.0001, 584 AChR 
clusters across three animals (n=3), and 680 AChR clusters (n=3), two sided Mann-
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Whitney U-test). Similar decreases were observed in E16 (27.66 versus 19.18, 
p<0.0001, 489 AChR clusters (n=4), and 463 AChR clusters (n=4), respectively, two 
sided Mann-Whitney U-test) and E18 (38.87 versus 29.96, p<0.0001, 627 AChR 
clusters (n=4), and 571 AChR clusters (n=4), respectively, two sided Mann-Whitney U-
test) as well, suggesting that NRG1 is involved in promoting peri-synaptic Schwann cell 
development, as shown in Fig. 12. 
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Figure12. Down-regulated NRG1 signaling affected peri-synaptic Schwann cell 
development in PITIBs. A. Representative images show that treatment with HBD-S-H4 
resulted in less degree of post-synaptic AChR cluster (BTX, green) territory association 
with Schwann cells (P0, red) in PITIBs at E14, E16, and E18. B. The histogram 
summarizes the normalized distribution (percentage of the number of observations per 
bin of total number within the group) between Saline (control) and HBD-S-H4 treated 
embryos and shows significant decrease of the association between AChR cluster 
territory and Schwann cell signals (E14, E16, E18, p<0.0001, two sided Mann-
Whitney U-test). Scale bar, 25μm. 
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Discussion 
Motor neurons and muscle targets are connected by NMJs, where the 
communication is conveyed between the nervous system and the muscular systems. 
NMJ development is a multi-stage process including an early stage, defined as motor 
axon extension toward targets to the initial axon-target contact; a middle stage, when 
pre-synaptic, post-synaptic, and peri-synaptic components differentiate to form mature 
synapses; and a late stage, which includes synapse elimination and life-long 
maintenance (Sanes and Lichtman, 1999a). The accomplishment of this developmental 
process is dependent on a variety of organizing molecules at the site of the NMJs, 
including NRG1.  
Here, we used three parameters to quantitatively measure NMJ development in 
chicken embryos. We proposed that the more each parameter changes between 
adjacent stages, the more dynamic NMJs are with respect to the components involved. 
The size of AChR clusters represents the net combination of AChR expression and 
turnover. The measure showed that there are two phases of steep increase for AChR 
cluster size: E7-E10 and E12-E14 are the most dynamic stages in AChR synthesis 
and/or receptor degradation. The two phases of AChR cluster size growth coincide with 
the stages of NMJ development. E7-E10 represents the initiation of innervation, as the 
early stage transitions to the middle stage. Accordingly, the major intramuscular 
branches have formed while the detailed arborization pattern has not been fully 
established.  The nerve terminals are close to the AChR clusters while pre- and post-
synaptic appositions have not been consolidated. The shorter distance facilitates 
soluble nerve-derived factors to function more locally. E12-E14 coincides with pre- and 
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post-synaptic differentiation, when the growth cones have transformed into pre-synaptic 
terminals specialized for neurotransmitter release with the accumulation of synaptic 
vesicles and vesicle-associated proteins. Post-synaptically, the clustering of AChR is 
likely to be strengthened by organizing factors directly from nerve terminals. The degree 
of pre- and post-synaptic apposition indicates the level of differentiation of both pre- and 
post synaptic structures.  The steady increase from E12 to E18 corresponds to the 
middle to late stages of NMJ development. The peri-synaptic Schwann cells start to 
engulf and cap the maturing NMJs from at E14 through E18.  
NRG1 isoforms are produced as trans-membrane precursors, some of which 
undergo proteolytic cleavage to become soluble proteins (Loeb, 2003, Mei and Xiong, 
2008). At the chicken NMJ, the accumulation of NRG1 immunoreactivity can be only 
detected in the synaptic basal lamina after E16, concurrent with the concentration of 
HSPGs (Loeb et al., 1999). Therefore, it is likely that, before being immobilized by 
HSPGs, released forms of NRG1 mainly function at distant sites by diffusion, such as 
the developing hindlimb muscles at E7, and the ALD muscle from E8-E10. In these 
areas at an early developmental stage, NRG1 promotes either AChR cluster density or 
AChR cluster size, depending on the muscle type. However, when pre- and post-
synaptic appositions start to develop approximately from E10, other stronger post-
synaptic organizing factors, such as agrin, take over to dominate the clustering of 
AChR, leaving the function of NRG1 dispensable afterward. NRG1 then transitions to a 
secondary modulatory signal for AChR expression or clustering. When concentrated at 
basal lamina from E16 by the interaction between HBD and HSPGs, NRG1 can fine-
tune other events at NMJs, such as pre- and post-synaptic appositions and peri-
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synaptic Schwann cell development. The modes of function of NRG1 at NMJs are 
illustrated in Fig. 13. 
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Figure13. A stage-dependent model of NRG1 signaling functions in NMJ 
development. A. During the early stage when motor axons extend toward targets for 
the initial axon-target contact, released soluble NRG1 proteins function as diffusible 
growth and differentiation factors to induce AChR cluster density in the hindlimb muscle 
mass and to increase cluster size in the ALD muscle. B. When pre-synaptic and post-
synaptic components differentiate at newly formed NMJs in the middle stage, NRG1 
supports the survival and further differentiation of the post-synaptic muscle cells which 
provide the motor axons with pre-synaptic organizers for the proper transport and 
aggregation of synaptic vesicles. C. In the middle-late stage, peri-synaptic Schwann cell 
development is dependent on neuron-derived NRG1. Both peri-synaptic Schwann cells 
and muscle targets express HSPGs on their cell surface to interact with soluble NRG1 
to potentiate NRG1 signaling. Potential reciprocal signaling between nerve terminals 
and muscle cells mediates the fine alignment of pre- and post-synaptic appositions. 
  
It is quite surprising to find that down-regulation of NRG1 signaling by antagonist 
treatment resulted in pre-synaptic defects in synaptic vesicle transport and terminal 
clustering at certain stages. Because the expression of NRG1 ErbB receptors is barely 
detectable in either motor neurons or in extending axons during the middle stage of 
NMJ development (unpublished data), it is likely that these defects arise indirectly 
through changes in Schwann cells or muscle cells.  Muscle-derived fibroblast growth 
factors (FGFs) of the 7/10/22 subfamily have been reported to regulate synaptic vesicle 
transport and clustering as nerve terminals form (Fox et al., 2007).  
It will be interesting to examine the expression level of FGF ligands and the 
activation of corresponding FGF receptors when NRG1 signaling is down-regulated. 
The potential indirect involvement of NRG1 in pre-synaptic apparatus assembly 
suggests the existence of reciprocal signaling between motor neurons and muscle 
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targets, where motor neurons release growth factors like NRG1 to support the 
expression of muscle-derived growth factors that play important roles in the regulation 
of pre-synaptic motor axon differentiation. A similar signaling network, mediated by 
NRG1 and neurotrophic factors such as BDNF, has been suggested to regulate 
Schwann cell development (Ma et al., 2011). Moreover, as shown in the results, the 
antagonist led to a decrease of pre- and post-synaptic apposition when the NMJs 
became mature, suggesting that NRG1 might also calibrate the specialization of pre-
synaptic machinery in the late stage as the final fine-tuning step. The decrease of the 
apposition seems to at least partially result from more ‘puncta’-like synaptic vesicle 
signals in antagonist-treated animals, suggesting that the distribution of the vesicles 
within the pre-synaptic apparatus might be altered when NRG1 signaling was down-
regulated in the late stage. However, it is not clear if the underlying mechanisms are the 
same as in the synaptic transport failure.  
Here, we found that over-expression of NRG1 resulted in the increase of AChR 
cluster density, without regulating AChR cluster size. However, Ngo et al. reported that 
exogenous NRG1 increased the size of developing AChR clusters when injected into 
muscles of embryonic mice (2011). The conditions differ in several ways. First, we used 
a different system to address this issue: they used embryonic mouse sternomastoid 
muscle while we assayed the AChR cluster in embryonic chick thigh muscle. 
Considering the difference of NMJ development among different species, NRG1 might 
play distinct roles in regulating the AChR cluster formation. Secondly, they assayed 
AChR cluster four hours after the exogenous application of NRG1 while we used in ovo 
electroporation to achieve over-expression and assayed the effects about four days 
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later. Therefore, their effects might be due to acute NRG1 stimulation onto developing 
myotubes while our result was closer to continuous NRG1 over-expression during the 
whole critical period for motor neurons to develop and innervate into limbs. Finally, they 
applied recombinant NRG1-β1 to muscle cells directly, while we used the full-length 
type I NRG1 coding sequence which gave us the advantage of utilizing an endogenous 
regulatory mechanism. Moreover, when NRG1 signaling was down-regulated by the 
application of antagonist, we found that AChR cluster size decreased slightly in ALD 
muscle but not in PITIBs, suggesting that NRG1s are actually involved in the regulation 
of AChR cluster size in our system. To add a new layer of complexity, ALD is mainly a 
multi-innervated slow-tonic muscle which is rare in mammalian species, suggesting the 
muscle-type-dependent function of NRG1s might be different in mammalian.  
Despite the difference between this dissertation and the report by Ngo et al., both 
studies show that during the early development stage, NRG1 plays important roles in 
regulating AChR cluster formation. Schmidt et al. recently reported that loss of 
neuromuscular NRG1-ErbB signaling destabilized anchoring of AChRs in the 
postsynaptic muscle membrane in adult animals (2011). Taken together, these new in 
vivo results support the notion that NRG1 signaling has multiple functions during NMJ 
development and maintenance. 
NRG1 signal plays important roles in Schwann cell migration, maturation, and 
myelination (Birchmeier and Nave, 2008, Ma et al., 2011), whereas the function of 
NRG1 in peri-synaptic Schwann cell development remains mostly unknown, mainly 
because the subpopulation does not express distinct molecular markers. We used 
antibody 1E8 targeting P0 protein to label peri-synaptic Schwann cells and calculated 
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the alignment between peri-synaptic Schwann cells and post-synaptic AChR clusters. In 
mice, it is believed that non-myelinating Schwann cell express low levels of P0 protein 
(Sanes and Lichtman, 1999b). However, a study in the frog also showed that peri-
synaptic Schwann cells express enough P0 protein for immunostaining, suggesting that 
there is variability in different aspects of NMJ development across species (Georgiou 
and Charlton, 1999). The result showed that some of the P0 signal was associated with 
post-synaptic AChR clusters, indicating that pre-synaptic Schwann cells were actually 
labeled. Although we have found that the development of peri-synaptic Schwann cells 
was disrupted when NRG1 signaling was down-regulated, the specific underlying 
mechanism remains to be determined in future studies. 
In summary, the data suggest that NRG1 has different roles in distinct aspects of 
NMJ development by inducing AChR cluster density and size in the early stage, 
regulating pre-synaptic synaptic vesicle recruitment in the middle stages, maintaining 
the pre- and post-synaptic apposition in the late stage, and promoting peri-synaptic 
Schwann cell development.  
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CHAPTER III 
EXPRESSION OF NEUREGULIN1 ISOFORMS IS REGULATED BY 
NEUROTROPHIC FACTORS AND AXON-TARGET INTERACTIONS  
Summary 
The neuregulin1s (NRG1s) are a family of alternatively spliced growth and 
differentiation factors that play important roles in many aspects of nervous system 
development and in disease. In motor neurons, NRG1 expression at the axon-Schwann 
cell and neuromuscular junctions is regulated by synaptic activity and neurotrophic 
factors; however, little is known about the mechanisms that control NRG1 isoform-
specific transcription, critical for the specific regulation of membrane-bound and 
secreted isoforms. Here we show that NRG1 expression of both types of isoforms 
increases in motor neurons that have extended axons in the chick embryo.  Limb bud 
ablation before the time of motor axon outgrowth prevents the induction of NRG1 
mRNA, suggesting that the limb bud supplies factors that promote NRG1 mRNA 
expression. Consistently, NRG1 induction can be rescued by adding back exogenous 
neurotrophic factors, including brain-derived neurotrophic factor (BDNF) and glial-cell-
line-derived neurotrophic factor (GDNF), but not nerve growth factor (NGF). As a means 
to explore the molecular basis for NRG1 transcriptional regulation, we measured the 
effects of neurotrophic factors on mRNA levels of the three major mammalian 
alternatively-spliced forms of NRG1 in rat embryonic ventral spinal cord cultures. BDNF 
induced a rapid and transient increase in type I and III NRG1 mRNA that peaked at 4 h 
and then returned to baseline.  No effects were seen on type II NRG1 mRNA. Specific 
inhibitors that blocked MAPK or PI3K signaling prevented this induction. While the 
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global transcription inhibitor Actinomycin D blocked BDNF-induced NRG1 gene 
induction, BDNF had no effects on mRNA degradation, suggesting that transcriptional 
activation, rather than message stability, drives BDNF-induced NRG1 mRNA induction.  
Consistently, BDNF was able to activate transcription of a reporter construct containing 
700bp of the 5’ regulatory region flanking the transcription start site of type I NRG1. 
Protein synthesis is also required for type I NRG1 mRNA transcription, because the 
translation inhibitor cycloheximide produced a super-induction of type I, but not type III 
NRG1 mRNA, possibly through a mechanism involving sustained activation of MAPK 
and PI3K.  These results reveal the existence of highly responsive, transient 
transcriptional regulatory mechanisms that differentially modulate NRG1 isoform 
expression as a function of extracellular and intracellular signaling cascades mediated 
by neurotrophic factors and axon-target interactions. Understanding these mechanisms 
will be important for elucidating the role of NRG1 in both development and in 
pathological disorders of the nervous system. 
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Materials and Methods  
Chick eggs, unilateral limb ablation and in ovo treatment 
Fertilized chicken eggs were obtained from Michigan State University Poultry Farms 
and incubated in a Kuhl rocking incubator at 50% humidity. Limb buds were removed 
unilaterally on E3 and embryos were returned to the incubator until the time indicated. In 
some experiments, recombinant BDNF, GDNF (Amgen), or NGF (Life Technologies) 
were added on E4 and E5 as described previously (Loeb et al., 2002, Ma et al., 2009). 
In brief, 1 μg/embryo/day of BDNF, GDNF, or NGF was prepared in saline containing 
0.2% BSA, and added onto the chorioallantoic membrane for two consecutive days. 
Embryos were collected at indicated times and processed for total RNA, or in situ 
hybridization combined with immunofluorescence staining as described below. Staging 
of chick embryos was determined according to the Hamburger-Hamilton (HH) stage 
series (Hamburger and Hamilton, 1951): E3 (stage 18-19); E4 (stage 23-24); E5 (stage 
26-27); E6 (stage 28-29). 
Immunofluorescence staining and in situ hybridization 
Embryos were fixed in 4% paraformaldehyde in PBS at 4°C overnight, washed in PBS, 
equilibrated in 30% sucrose in PBS, and sectioned into 20 μm sections. Neuregulin1 
was labeled using 1310 antibodies against the proNRG1 precursor cytoplasmic tail 
(Loeb et al., 1999). RT-97 (1:50) and Islet1/2 (1:50) were obtained from the 
Developmental Studies Hybridoma Bank at the University of Iowa, to label 
neurofilament and spinal cord motor neurons, respectively. Sections were incubated 
with antibodies in blocking solution (10% normal goat serum, 0.1% Triton X-100 in PBS) 
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overnight at 4°C, followed by incubation with the corresponding goat anti-mouse or anti-
rabbit Alexa Fluor antibodies (1:500; Life Technologies) for visualization. Radioactive in 
situ hybridization was performed using 35S-labeled RNA probes as previously described 
(Beaumont et al., 2012). In brief, sense and antisense 35S-labeled RNA probes were 
generated from linearized full-length chicken proARIA cDNA clones by in 
vitro transcription (Life Technologies). Probes were purified on NuClean R50 Sephadex 
columns (Shelton Scientific). Tissues were hybridized at 52°C overnight, followed by 
washing, and dehydrated in ethanol. Slides were then dipped in photographic emulsion 
(Kodak NTB), dried, and exposed for 7 days at 4°C.  
Imaging and quantitative analysis. 
Digital images were captured using a Nikon Eclipse E600 microscope with a Princeton 
Instruments Micromax cooled CCD digital camera. Signal intensity was quantified using 
MetaMorph image analysis software (Molecular Devices). In the spinal cord, the lateral 
portions of the lateral motor column on each section were first defined as regions of 
interests (ROI) based on weaker Islet-1/2 signal on the most lateral part of the ventral 
spinal cord. The intensity of in situ hybridization signals were measured using total pixel 
grey value above signal threshold within each ROI. The ratio of operated/control side 
was calculated by dividing average grey value of the operated side by the counterpart of 
the control side within the same section.  
Primary spinal cord motor neuron culture 
Primary spinal cord motor neurons were cultured as described previously (Loeb and 
Fischbach, 1997). Briefly, ventral spinal cords were dissected from timed-pregnant 
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Sprague Dawley rat embryos (Harlan). Cultures of ventral horn neurons were prepared 
from the anterior two-thirds spinal cords of embryonic day 15 (E15) rat embryos and 
were dissociated in HBSS containing 0.1% trypsin. Cells were placed on laminin and 
poly-D-lysine-coated 24-well plates at density of 200,000 cells/cm2 in Leibovitz's L-15 
Glutamax Medium supplemented with N-2 supplement, MEM vitamin solution, 
penicillin/streptomycin (Life Technologies), 6 mM NaHCO3, 6 μg/ml chick E11 pectoral 
muscle extract, and 54 μg/ml imidazole. Cultures were maintained at 37°C with 5% 
CO2.  At day in vitro 3 (DIV3), cultures were treated with BDNF, GDNF, or NT-3 
accordingly for indicated time periods. In some experiments, inhibitors were added 
30 min before neurotrophic factors. At the end of stimulation, cells were washed with 
cold PBS and subjected to total RNA or protein extraction, as described below.  
RNA isolation and RT-qPCR 
Five- to six-somite-long segments of lumbar spinal cords were harvested from unilateral 
limb-ablated chick embryos at E6 and then separated from the midline for RNA 
extraction. Total RNA from both tissue and cell cultures was isolated using an RNeasy 
mini kit (Qiagen). Equal amounts of total RNAs were reverse transcribed using oligo-dT 
by the Superscript First-Standart Synthesis System (Life Technologies). Chick NRG1 
transcripts were detected as previously described (Ma et al., 2011). Rat type I and type 
II NRG1 were measured by Rn00580917_m1 and Rn01482172_m1, respectively; type 
III NRG1 were detected by: forward primer 5′-TCCTAAACTTTCCACATCGACATC; 
reverse primer 5′-TCTCATAAAGTGCGCGGAG; and Taqman probe 6FAM-
ACGACTGGGACCAGC. Rat GAPDH was detected by Rn99999916_s1 for 
normalization (Life Technologies). Levels of isoforms of NRG1 mRNA were first 
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normalized by GAPDH, whose levels were revealed in the same reactions and then 
normalized by control. Quantitative PCR data were collected from at least three 
biological replicates, and ∆∆Ct was used for calculations. 
Protein isolation and immunoblotting 
Total protein from cultured ventral spinal cord neurons was extracted using RIPA lysis 
and extraction buffer containing 25 mM Tris, pH 7.6, 150 mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS, and Halt Protease and Phosphatase Inhibitor Cocktail 
(Thermo Scientific). Equal amount of protein samples were loaded for immunoblotting 
using antibodies from Cell Signaling at the following dilutions: Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) (1:1000, #4370), p44/42 MAPK (Erk1/2) (1:1000, #4695); 
Phospho-p38 MAPK (Thr180/Tyr182) (1:1000, #4511), p38 MAPK(1:1000, #8690); 
Phospho-Akt (Ser473) (1:1000, #4060), Akt (pan) (1:1000, #4685). SuperSignal West 
Pico Chemiluminescent Substrate (Thermo Scientific) was used for signal detection. 
Blots were first probed with antibodies against phospho-proteins, and then stripped for 
reprobing with antibodies against pan-proteins.  
 Dual luciferase reporter assay 
5′ flanking regions of type I and III NRG1s were amplified by PCR from rat genomic 
DNA using forward primer 5’-TGCTTAGGAAGAAGCTAGAGTGAGT, and reverse 
primer 5’-TCAGACATCTCGCCGAAGATGA for type I; forward primer 5’-
TAAGAGTCCTGTGAGTGAAC, and reverse primer 5’-ATGTCTGGGGAATAAATCTC 
for type III. They were subcloned into pGL3B vector upstream to the firefly luciferase 
gene, and verified by sequencing. Dissociated ventral spinal cord cells were 
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cotransfected by electroporation (Neon Transfection System, Life Technologies) with 
type I promoter-Luc or type III promoter-Luc together with thymidine kinase promoter-
Renilla luciferase reporter plasmid (pRL-TK) at ratio of 50:1. 12 hours after transfection, 
cells were treated with BDNF, NGF or the combination of BDNF and NGF as indicated 
for 24 h before lysis. Firefly and Renilla luciferase activities were assayed using Dual-
Luciferase Reporter Assay System (Promega) using a Fluoroskan Ascent microplate 
luminometer (Thermo Scientific). Firefly luciferase activity was normalized to 
Renilla luciferase activity to reduce inter-experiment sample variation.  
Statistical analysis 
A paired two-tailed Student’s t-test was used to analyze differences between two 
treatment groups. Statistical differences for multiple group comparisons were calculated 
by one-way ANOVA followed by Dunnett’s post hoc test. For comparisons of multiple 
groups with different treatments, two-way ANOVA followed by Bonferroni’s post hoc test 
by comparison to control was used. Normalized values were averaged and reported as 
the mean ± SEM of at least three independent experiments. Statistical significance is 
presented as * p<0.05, ** p<0.01, *** p<0.001.  
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Results 
Axon-target interactions regulate NRG1 mRNA expression 
 It has been observed that NRG1 protein and mRNA increases in spinal motor 
neurons following their birth and migration towards the lateral portion of the developing 
spinal cord in chicken embryos (Loeb et al., 1999). ProNRG1 expression is at the 
highest level in those motor neurons (homeodomain motor neuron marker Islet-1/2+) 
that have completed their migration and have extended their axons into the surrounding 
mesoderm (Fig. 14). Consistent with the protein level, increase of NRG1 mRNA in 
lateral motor column was observed during development (Unpublished data performed 
by Dr. Vaagn Zakarian). This observation suggests that peripheral mesoderm provides 
extrinsic factors to coordinate NRG1 expression.  
To examine the effect of axon-target interactions on NRG1 expression, unilateral 
hind limb bud ablation was performed in ovo at E2.5, prior to axon outgrowth into the 
limb bud (Tosney and Landmesser, 1985) (Fig. 15A, 15B). With this model, motor axons 
spiral into a ball in the absence of a target to innervate. After limb bud ablation, but 
before the period of programmed cell death that starts at E6, NRG1 mRNA levels did 
not increase on the ablated side as they do on the control side in the lateral portion of 
the lateral motor column (LMCL) that normally innervates the dorsal limb bud (Fig. 15C, 
15D). The weakly positive Islet-1/2 marker is used to label the lateral LMC, which shows 
no reduction of motor neuron numbers even after ablation (Unpublished data performed 
by Abdelkrim Hmadcha). This marker was used in double labeling radioactive in situ 
experiments in Fig. 15C to quantify the in situ signal. The results provide evidence that 
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target-derived factors were necessary for directing the expression of NRG1. To 
characterize the composition of NRG1 isoforms in the operated animals, RT-qPCR 
using isoform-specific primers was performed. Compared to the control side, both IG-
NRG1 (type I/II) and CRD-NRG1 (type III) were significantly reduced on the ipsilateral 
side, suggesting that axon-target interactions are important to induce both of the major 
NRG1 isoform classes (Fig. 15E).  
 
Figure14. ProNRG1 expression in motor neurons and their axons. A. An HH stage 
18 chicken spinal cord was labeled with 1310 (green) and Islet-1/2 (red), showing that 
motor neurons (Islet-1/2+) located laterally expressed a high level of NRG1 (1310). In 
contrast, medial motor neurons had little NRG1 expression at this stage. B. Zoomed-in 
images of right side ventral spinal cord area. (Unpublished data performed by Abdelkrim 
Hmadcha and Vaagn Zakarian). 
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Figure15. Motor neurons that fail to contact their targets express lower NRG1 
mRNA levels. A. Removal of the apical ectodermal ridge at E2.5 results in a unilateral 
limbless chicken embryo at E6. B. Sections through the lumbar level show motor axons 
(RT-97, red) expressing NRG1 (1310, green) rolled into a ball (arrow), while 
contralateral axons innervate the limb normally. (Unpublished data performed by Vaagn 
Zakarian). C. NRG1 mRNA levels were quantified using a double-labeling with 
immunofluorescence using islet-1/2 antibodies followed by radioactive in situ 
hybridization with a pan-NRG1 probe.  In situ hybridization signals were quantified from 
the LMCL (ROI determined by weaker Islet-1/2 immunoreactivity in the most lateral part 
of the ventral horn) and the ratio of NRG1 mRNA expression on the operated/control 
side for each embryo was determined from E4-E6. (Unpublished data performed by 
Abdelkrim Hmadcha and Vaagn Zakarian). D. Limb bud ablation led to reduced NRG1 
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levels the LMCL at E5 and E6. (Unpublished data performed by Abdelkrim Hmadcha 
and Vaagn Zakarian). E. In order to determine which NRG1 isoforms were responsible 
for this reduction, control and ablated sides of the ventral lumbar spinal cord were 
isolated and HBD-NRG1 (type I/II) and CRD-NRG1 (type III) were quantified qPCR 
(n=10) after normalization to GAPDH for each animal.  Both of these showed reduced 
mRNA levels on the ablated side. * p<0.05, paired two-tailed Student’s t-test. 
 
Neurotrophic factors restore NRG1 mRNA reduction in motor neurons lacking 
targets. 
A lack of neurotrophic support is one possible explanation for the failure of NRG1 
mRNA induction following limb bud ablation.  Developing muscles provide a range of 
neurotrophic factors that support motor neuron survival and neuromuscular junction 
development (Levi-Montalcini and Calissano, 1979, Henderson et al., 1993, Henderson 
et al., 1994).  These factors have distinct expression profiles at different developmental 
stages. Therefore, we asked whether exogenous BDNF, GDNF, or NGF could rescue 
NRG1 mRNA expression after unilateral limb ablation. This was determined by 
measuring the ratio of NRG1 mRNA levels in the LMCL on the operated versus control 
sides of the spinal cord at E6 with or without addition of these factors at E4 (Fig. 16A) 
(Unpublished data performed by Dr. Abdelkrim Hmadcha). While both BDNF and GDNF 
maintained normal NRG1 mRNA levels in motor neurons that lack targets, NGF failed to 
rescue expression (Fig. 16A, 16B).  This is consistent with their known actions, because 
muscle- and Schwann cell-derived BDNF and GDNF have been shown to be potent 
survival factors for motor neurons (Yan et al., 1992, Henderson et al., 1994), whereas 
NGF and its receptors have little effect on motor system development (Funakoshi et al., 
1993, Ip et al., 2001).  
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Figure16. NRG1 expression can be rescued by BDNF or GDNF after limb bud 
ablation. A. Representative images are shown for in situ hybridization from the ventral 
spinal cords of limb-bud ablated chick embryos treated with Saline, BDNF, GDNF, or 
NGF using a pan-NRG1 probe. B. Quantitative analysis using the ratio of NRG1 in 
operated/control sides showed that BDNF and GDNF, but not NGF, rescued the 
decrease of NRG1 mRNA on the ablated side. Data are reported as the mean ± SEM of 
n=10, 11, 3, 5, for Control, BDNF, GDNF, NGF, respectively, * p<0.05, ** p<0.01, one-
way ANOVA followed by Bonferroni’s post hoc test by comparison to control. Scale bar, 
50μm (Unpublished data performed by Abdelkrim Hmadcha). 
 
Type I and type III NRG1 mRNAs are rapidly and transiently up-regulated by 
neurotrophic factors in mammalian motor neuron cultures. 
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To further address the mechanism by which neurotrophic factors regulate NRG1 
mRNA expression, we utilized an established rat embryonic ventral spinal cord motor 
neuron culture system where we previously have shown rapid (within 4 hours) effects of 
BDNF and GDNF on NRG1 mRNA levels (Loeb et al., 1999). Using isoform-specific 
qPCR, we found that type I NRG1 mRNA was induced by both BDNF and GDNF, 
whereas type III NRG1 mRNA was induced by BDNF only to a smaller extent (Fig. 
17A). No significant change was observed in type II NRG1 mRNA levels in response to 
either neurotrophic factor (Fig. 17A). Next, to examine whether the transcriptional 
kinetics of the three isoforms could be regulated by neurotrophic factors, we chose 
BDNF, for its greater effects on transcription induction in the previous experiment, to 
stimulate cells for different period of time and measured corresponding isoform mRNA 
levels. The kinetics of mRNA induction for type I NRG1 mRNA peaked at 4 h, but 
declined rapidly by 6 h, and returned to baseline 8 h after BDNF application. Type III 
NRG1 transcripts were also induced at 4 h; however, it was not reduced at 6 h, but 
returned to baseline levels by 8 h. These kinetic patterns were seen consistently on 
multiple experiments for type I (n=3) and type III (n=3) (Fig. 17B). These results 
demonstrate that both type I and type III, but not type II, NRG1 mRNA levels are rapidly 
and transiently induced with BDNF stimulation, but with distinct temporal profiles, 
suggesting both common and unique regulatory mechanisms.  
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Figure17. Differential regulation of NRG1 isoform mRNA levels by neurotrophic 
factors in rat embryonic ventral spinal cord cultures. A. Disassociated E15 rat 
embryonic ventral spinal cords were cultured for three days and then treated with and 
without BDNF (100 ng/ml) or GDNF (100 ng/ml) for 4 h. BDNF and GDNF induced type 
I greater than type III, but not type II NRG1 mRNA using isoform-specific qPCR. B. A 
time course revealed that BDNF (100 ng/ml) induces type I NRG1 mRNA maximally and 
transiently at 4 h. Type III is induced less at 4 h, but stays up longer than type I.  Type II 
was unaffected by BDNF.  Data reported are the mean ± SEM of at least three 
independent experiments. * p<0.05, ** p<0.01, *** p<0.001, two-way ANOVA followed 
by Bonferroni’s post hoc test by comparison to control (A), or 0h (B). 
 
TrkB, MAPK and PI3K signaling are required for BDNF-induced NRG1 expression 
To explore the signaling pathways involved in the regulation of type I and type III 
NRG1 mRNA by BDNF, we pretreated cultured cells with specific inhibitors prior to 
BDNF application. BDNF binds to either the TrkB tyrosine kinase or the low-affinity 
nerve growth factor receptor p75 and is known to lead to the activation of MAPK, 
phosphotidylinositol-3 kinase (PI3K) and phospholipase C-γ (PLC-γ) (Segal, 2003).  
Inhibition of TrkB activation by K-252a blocked NRG1 type I and type III mRNA 
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induction by BDNF at 4 h (Fig. 18A, 18B). Furthermore, inhibition of either MAPK by the 
MEK inhibitor PD98059 or U0126, or PI3K by LY294002 or Wortmannin, blocked NRG1 
mRNA induction by BDNF (Fig. 18C, 18D). These findings suggest that TrkB, MAPK, 
and PI3K signaling pathways are all involved in NRG1 type I and III mRNA induction.  
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Figure18. Trk receptor, MEK, and PI3K inhibitors block the effect of BDNF on 
NRG1 mRNA.  Rat embryonic ventral spinal cord cultures were exposed to K-252a (200 
nM) (A, B) or PD98059 (10 μM), U0126 (10 μM), LY294002 (50 μM), or Wortmannin 
(200 nM) (C, D) for 30 min prior to adding BDNF (100 ng/ml) for 4 h. The inhibitor 
pretreatment resulted in the abrogation of BDNF induction on both type I and type III 
NRG1 compared to the diluents alone (no inhibitor). Data are reported as the mean ± 
SEM of at least three independent experiments. *** p<0.001, two-way ANOVA followed 
by Bonferroni’s post hoc test by comparison to control. 
 
BDNF-induced NRG1 induction requires new transcription  
 The increase in mRNA levels could have resulted from either an increased rate 
of transcription, mRNA stabilization, or both. To distinguish between these possibilities, 
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we measured mRNA levels after BDNF-treatment in the presence or absence of the 
transcription inhibitor Actinomycin D (ActD). Pretreatment with ActD for 30 minutes 
completely prevented NRG1 mRNA induction by BDNF, demonstrating that ongoing 
gene transcription is necessary for BDNF-evoked type I and III NRG1 mRNA up-
regulation (Fig. 19A). To address whether the turnover rate of NRG1 mRNA is altered 
by BDNF, cultures were treated with ActD in the presence and absence of BDNF and 
mRNA levels were measured as a function of time. Interestingly, type I NRG1 mRNA 
was relatively short-lived, with a half-life of about 1h, whereas type III NRG1 mRNA was 
more stable, with a half-life of about 2h (Fig. 19B). Because the presence or absence of 
BDNF had no clear effects on the turnover ratio of either type I or III NRG1 mRNA, 
these findings suggest the most important effect of BDNF is on transcriptional activation 
rather than on mRNA stability. 
 Given the importance of transcription for BDNF induction, we next investigated 
the effects of BDNF on the 5’ cis-elements upstream to type I and III NRG1 transcripts 
in rat embryonic ventral spinal cord cultures. Firefly luciferase constructs were prepared 
containing the 5’ promoter regions flanking the transcription start sites for rat type I (-
649 to +5) and type III (-1343 to +31) NRG1 (Fig. 20A). Each of these constructs was 
co-electroporated with the control vector pRL-TK in order to normalize the NRG1 
induced luciferase activity with Renilla luciferase activity. After 24h, BDNF induced the 
type I promoter-driven luciferase (Fig. 20B).  These findings suggest that cis-acting 
elements contribute to type I NRG1 transcription induced by BDNF. 
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Figure19. BDNF promotes transcription but has no effect on mRNA stability. A. 
Rat embryonic ventral spinal cords were treated with or without actinomycin D (ActD, 2 
µg/ml) for 30 minutes before BDNF (100 ng/ml) stimulation, and harvested at 4h. B. A 
time course of NRG1 decay with or without BDNF/ActD shows that BDNF does not 
change the rate of mRNA degradation rate for both type I and III isoforms. Decay curves 
were fitted to a single-phase decay curve to calculate a t1/2=62 min (R2 = 0.93) for type I 
with ActD and t1/2=67 min (R2 = 0.92) for ActD + BDNF. In contrast, type III NRG1 had a 
t1/2=120 min (R2 = 0.92) for ActD and t1/2=111 min (R2 = 0.85) for ActD + BDNF 
treatment.  
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Figure20. The 5′-flanking region of type I NRG1 is sufficient for BDNF induction of 
transcription.  A. 5’ promoter regions for type I and type III NRG1 were cloned into a 
luciferase reporter plasmid as indicated.  B. Disassociated rat embryonic ventral spinal 
cords were electroporated with each construct together with the pRL-TK control vector. 
12 h after electroporation, cells were treated with or without BDNF (100 ng/ml) for 24 h 
before luciferase activity was measured. BDNF treatment induced the type I promoter-
driven luciferase activity significantly, whereas there was only a non-significant increase 
using the type III promoter. Transcriptional activities were shown by fold change 
compared to control, after normalization for transfection efficiency by the activity of 
Renilla luciferase. Data are reported as the mean ± SEM of at least twelve biological 
replicates, ** p< 0.01, paired two-tailed Student’s t-test. 
 
Protein synthesis is required to maintain type I NRG1 mRNA transcription  
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The transient nature of NRG1 mRNA induction by BDNF could have important 
biological implications.  The mechanism by which NRG1 transcription is precisely shut 
off after 4-6 hours following BDNF exposure was assessed using the protein synthesis 
inhibitor cycloheximide (CHX) in cultured ventral spinal cord neurons with and without 
BDNF treatment. Remarkably, CHX treatment prevented the down-regulation of type I 
NRG1 after 4 h of BDNF treatment, and instead led to a further almost 10-fold induction.  
Even in the absence of BDNF treatment, CHX produced a steady increase of type I 
NRG1 mRNA, suggesting an additional regulatory mechanism that promotes NRG1 
type I mRNA induction, independent of BDNF (Fig. 21A). In contrast, CHX had no 
effects on type III NRG1 expression (Fig. 21B). 
 This ‘superinduction’ of type I NRG1 could either be due to increased gene 
transcription or reduced degradation.  However, the kinetics of type I NRG1 mRNA 
stability were unchanged in the presence of CHX, suggesting that the effect is again 
related to increased transcription (Fig. 21C).  In light of the requirement for both MAPK 
and PI3K signaling from Fig. 5, we asked whether CHX affected the activation of both 
MAPK and PI3K signaling after BDNF stimulation in the presence and absence of CHX 
(Fig. 21D).  In contrast to a rapid, transient induction of pERK, p38, and pAKT (peaked 
at 30 min), BDNF treatment in the presence of CHX produced a more sustained, long 
term activation of all of these signaling intermediates with the greatest effect on pERK. 
These results suggest that protein synthesis is required to down-regulate long-term 
signaling effects of BDNF, with the greatest effect on MAPK signaling.  These results 
also show additional differences in the transcriptional regulatory mechanisms between 
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type I and type III NRG1 forms because there was no effect of blocking protein 
synthesis on type III forms. 
 
 
Figure21. Protein synthesis is required for the down-regulating NRG1 mRNA after 
BDNF-induced stimulation.  A. Rat embryonic ventral spinal cord cultures were 
pretreated with or without cycloheximide (CHX, 20 µg/ml) for 30 minutes before BDNF 
(100 ng/ml) stimulation. NRG1 type I mRNA levels were elevated significantly by CHX 
alone and super-induced with both CHX and BDNF. B. CHX had no clear effect on type 
III NRG1 expression. C. While CHX alone led to increased mRNA levels, CHX +ActD 
with or without BDNF had no effect on the rate of decay of type I NRG1 mRNA. Data 
are reported as the mean ± SEM of at least three independent experiments. * p<0.05, ** 
p<0.01, *** p<0.001, two-way ANOVA followed by Bonferroni’s post hoc test by 
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comparison to 0 h.  D. CHX prevented the normal reduction in ERK, p38 and AKT 
signaling after BDNF treatment of rat embryonic ventral spinal cord cultures. 
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Discussion 
A reciprocal axon-target feedback loop mediated by NRG1 and neurotrophic 
factors  
Both neuron-derived NRG1 and target-derived neurotrophic factors have been 
implicated in neuromuscular system development. The functions of these mediators rely 
not only on the dynamic distribution of their receptors, but also on the temporal and 
spatial expression profile of the ligands. This diversity allows a multi-directional 
crosstalk between cells that can be both temporally and spatially restricted, depending 
on the need biologically.  
Here we have focused on extracellular signaling mechanisms that underlie axon-
target interactions in the developing spinal cord and limb bud. We show that axon-target 
interactions promote NRG1 expression in spinal motor neurons and that this effect can 
be replicated by target-derived neurotrophic factors, such as BDNF and GDNF.  In vitro, 
we show that BDNF induces a rapid, yet transient up-regulation of NRG1 mRNA that 
operates through de novo transcription and is mediated by TrkB-MAPK and TrkB-PI3k 
signaling pathways as well as by distinct 5’ regulatory cis-elements.  The rapid (4 h) 
nature of the induction may be important to increase transcription in only those axons 
that make appropriate contact with their target.  The transient nature of the induction 
(sharply falls after 4 h) requires protein synthesis and is associated with a rapid shut 
down of the TrkB signaling cascades.  Biologically, this could be important to limit NRG1 
expression in axons that do not have sustained contact with their targets.  For secreted 
(type I) forms of NRG1, in addition to these transcriptional mechanisms, we have 
previously shown that BDNF can work post-translationally to promote the local release 
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of NRG1 from axons via a mechanism that requires protein kinase C-δ (Esper and 
Loeb, 2004, 2009). 
In addition to survival, target-derived neurotrophic factors have been implicated 
in supporting motor neuron function by eliciting transcriptional and translational changes 
(Chowdary et al., 2012). In the present study, deprivation of target-derived neurotrophic 
factors by unilateral removal of developing limb buds prior to the period of programmed 
cell death did not lead to programmed cell death, but did lead to changes in two out of 
the three major spliced forms of NRG1.  How neurotrophic factor signaling in axons is 
relayed to motor neuron nuclei is not entirely clear, but has been extensively studied 
(Segal, 2003, Zweifel et al., 2005).  Neurotrophic factor signaling pathways can also 
differ depending on the cellular localization of their receptors (Chowdary et al., 2012). 
For example, retrograde NGF-TrkA signaling on axons results in Erk5 activation to 
mediate NGF pro-survival signaling in dorsal root ganglion cells, while activation of TrkA 
in the cell bodies of these neurons uses Erk1/2 activation (Watson et al., 2001). Another 
level of complexity is that there are a number of seemingly redundant neurotrophic 
factors that can converge on common pathways.  Here, we found that both BDNF and 
GDNF could rescue NRG1 expression after limb bud ablation while NGF failed.  
Although this is consistent with the expression of profiles of their receptors, the crosstalk 
and downstream differences in signaling pathways from each factor adds additional 
complexity to this communication ‘language.’   
The complexity of NRG1 gene structure and isoform-specific expression  
 The human NRG1 gene is one of the longest and most complex genes in the 
genome, and is located on chromosome 8p12 and spans over 1 Mbp.  Recent studies 
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from the ENCODE project have shown regions within this gene that have DNase 
hypersensitivity implicating the presence of cis-regulatory elements (Rosenbloom et al., 
2013). One of the highest DNase-sensitive clusters is located -1-3 kb to the transcription 
start site of type I NRG1. Consistently, this enrichment region has high density of 
H3K27Ac and H3K4Me3 histones and transcriptional factor binding sites, determined by 
ChIP-seq analysis. All of these markers suggest that the ~4-5 kb DNA fragment might 
be an important regulatory region for type I NRG1 expression (Rosenbloom et al., 
2013). Consistently, we showed that BDNF can induce transcription of a portion of this 
cis-element.  It would be worthwhile to investigate if this region, especially within the first 
intron that has not been analyzed previously (Frensing et al., 2008, Liu et al., 2011), is 
responsible for the binding of regulatory factors induced by neurotrophic factor 
signaling.  
 Alternative splicing produces a daunting array of NRG1 proteins that have been 
actively investigated over the years (Falls, 2003).  In the current study we focused on 
three major protein forms that have been shown to have important differences in how 
and where they signal.  For example, type I and II forms both produce secreted proteins 
that have heparin-binding domains, but type II has an additional N-terminal Kringle 
domain of unclear function.  Despite the similarity, we found that BDNF had no effect on 
type II NRG1 transcription, but affected both types I and III.  Type III NRG1 isoforms are 
unique in that they have a second membrane-spanning region thought to activate its 
receptors through direct cell-cell interactions (Wang et al., 2001).  While BDNF induced 
both type I and type III NRG1 forms by 4 h after administration, there were differences 
in both the magnitude of the effect and the kinetics.  Type III NRG1 induction by BDNF 
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was lower, but with a longer time course (over 6 h), and was more slowly degraded than 
type I NRG1.  In addition, the BDNF effect on the 5’ cis-regulatory type III elements was 
less strong than for type I NRG1.  Finally, the mechanism requiring protein synthesis 
that shuts off type I NRG1 expression does not occur for type III forms, because 
cycloheximide had no effects on type III NRG1.  Taken together, each splice form has 
transcriptional and post-transcriptional regulatory machinery that can fine-tune its 
expression, leading to a dynamic spatially and temporally unique pattern of NRG1 
signaling in motor neurons.  
Wider roles for NRG1-BDNF reciprocal signaling in the nervous system  
 Both NRG1, neurotrophic factors, and their respective receptor systems have 
been shown to play critical roles in many aspects of nervous system development and 
in disease. For example, both signaling pathways are involved in long-term potentiation 
(LTP) in the hippocampus; however, studies have shown opposite effects with BDNF 
facilitating and NRG1 suppressing LTP (Patterson et al., 1996, Huang et al., 2000, 
Chen et al., 2010).  The expression of BDNF and NRG1 are tightly regulated by 
neuronal activity both at the neuromuscular junction (Loeb et al., 2002) and in the CNS 
(Flavell and Greenberg, 2008, Liu et al., 2011). However, the link between these two 
signaling pathways in the CNS has not been investigated. Thus, similar regulatory 
machinery might exist in the CNS as we have found peripherally here. Models of 
epilepsy have also been used to show activity dependence. Activity-dependent 
transcription of BDNF has been shown to promote epileptogenesis (He et al., 2004) and 
NRG1 mRNA increases in the hippocampus after a single electrical stimulation-induced 
seizure (Tan et al., 2012).   Finally, NRG1 has recently been implicated in models of 
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chronic pain after nerve injury (Calvo et al., 2010) and in both human tissues and an 
animal model of ALS through activation of microglia (Song et al., 2012). Understanding 
extracellular signaling through neurotrophic factors as well as the intracellular signaling 
cascades that promote NRG1 expression could therefore be used to develop 
therapeutic targets for these disorders. 
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CHAPTER IV 
CONCLUSIONS AND SIGNIFICANCE 
The body of work in this dissertation investigates the role of neuregulin1 (NRG1) 
in the development of the neuromuscular junction (NMJ) and develops an 
understanding of the molecular mechanisms by which differential expression of NRG1 
isoforms are regulated by neurotrophic factors and axon-target interactions. In Chapter 
II, a quantitative morphometric analysis of NMJ development was developed, which 
took into account synaptic size and density, together with the apposition of pre- and 
post-synaptic components and the alignment of peri-synaptic Schwann cells. On this 
background, data were presented suggesting that NRG1 promotes acetylcholine 
receptor (AChR) cluster density and size in the early stage. While in the later 
developmental stages, NRG1 signaling is involved in the processes of synaptic vesicle 
accumulation at nerve terminals, pre- and post-synaptic apposition, and peri-synaptic 
development. Data described in this chapter suggests that NRG1 plays distinct roles in 
multiple aspects of NMJ development in different developmental stages. In Chapter III, 
several lines of evidence were provided suggesting that expression of NRG1 isoforms in 
spinal cord motor neurons is regulated by target-derived neurotrophic factors such as 
brain-derived neurotrophic factor (BDNF) and glial-cell-line-derived neurotrophic factor 
(GDNF). The observation was expanded further, where data were presented that the 
transcription of type I NRG1 can be induced by neurotrophic factors in a temporal 
specific manner and type III can also be induced to a smaller extent. Further, it was 
demonstrated that the induction is mediated by both TrkB-PI3K and TrkB-MAPK 
signaling, mainly through transcription activation. Data were presented suggesting that 
 
86 
 
a 5’ regulatory region flanking to the transcription start site is required for BDNF-induced 
type I NRG1 expression. Finally, it was shown that protein synthesis is necessary for 
type I NRG1 induction but not type III. Cycloheximide, a protein synthesis inhibitor 
super-induced type I NRG1 transcription, at least partially, by maintaining the activation 
of intercellular signaling pathways. These results suggested that expression of NRG1 
isoforms in spinal cord motor neurons is regulated by neurotrophic factors and axon-
target interactions through distinct molecular mechanisms, which can contribute to their 
versatile expression profiles and functions at NMJs. 
The data presented in this dissertation are consistent with the idea that NRG1 
plays modulatory roles in NMJ development. Moreover, this is the first in vivo 
developmental study showing that NRG1 plays multiple roles at NMJs along with the 
different developmental stages, including post-synaptic AChR clustering in the early 
stage; synaptic vesicle transport and localization in the middle stage; pre- and post-
synaptic apposition, and peri-synaptic Schwann cell development in the late stage. The 
data presented here also reveal that spinal cord motor neuron-derived NRG1 and 
target-derived neurotrophic factors form a reciprocal system for axon-target 
communication, by which neurotrophic factors regulate different isoforms of NRG1 
expression to account for their distinct roles in neuromuscular system development. 
Aside from significantly adding to our understanding of endogenous roles of NRG1 in 
regulating NMJ formation and function, and how the isoforms are regulated by 
neurotrophic factors during development in the peripheral nervous system (PNS), the 
findings here may have important implications in understanding and treating human 
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diseases which involve the PNS and the muscular system. The mechanisms in the PNS 
could be potentially translated to the central nervous system (CNS) disorders as well. 
Isoforms of NRG1 are essential for everything from heart development to glia 
differentiation (Esper et al., 2006). At NMJs, it has been suggested that they promote 
the expression of AChR subunits and other post-synaptic components based on the 
observations in vitro (Brenner et al., 1990). However, the expression of these genes 
was barely reduced and the NMJs form on schedule when NRG1 signaling is disrupted 
in the neuromuscular system (Escher et al., 2005). NRG1 appears to be non-essential 
for NMJ development, since most of the NMJ defects in animals with disrupted NRG1 
signaling are modest, transient, and can be compensated. These findings lead to an 
updated hypothesis that the family of growth factors plays modulatory, and maybe 
secondary, roles in modifying NMJ structure. The work from the dissertation has found 
that NRG1 has multiple functions at NMJs during development, and, consistent with the 
previous studies, their roles lean toward subtle and fine-tuning mechanisms, compared 
to the other dictating molecular signals such as Agrin-Lrp4-MuSK. As for their mode of 
functions, it has been shown that NRG1 can work synergistically with Agrin to promote 
post-synaptic AChR expression and clustering by potentiating MuSK phosphorylation (Li 
et al., 2004a, Ngo et al., 2012). Consistently, it has also been suggested that Erbin can 
bind to ErbB2 and MuSK to form a Erbin-ErbB2-MuSK complex at the synaptic site to 
mediate the induction of AChR expression and clustering, and myelination (Tao et al., 
2009, Simeone et al., 2010). Thus, NRG1 can serve as a second-order regulator upon 
Agrin to direct post-synaptic differentiation. Besides, NRG1 can regulate NMJ 
maintenance alone by stabilizing the post-synaptic apparatus via phosphorylation of α-
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dystrobrevin (Schmidt et al., 2011). Therefore, NRG1-ErbB can either work alone or 
function as a regulator to other signals at NMJs, depending on the developmental 
stages and extracellular or intracellular signals in the environment. 
Minor factors like NRG1 can have major impacts, especially in the dynamic and 
slow developmental processes that require resilient signals that are subject to 
adjustment by activity or micro-environmental change. Pronounced plasticity occurs 
during postnatal pruning and maintenance with constant functional and morphological 
remodeling, despite overall dimensions remaining stable (Wilson and Deschenes, 2005, 
Tapia et al., 2012). Remodeling of the NMJ can also be amplified with alterations 
in neuromuscular activity such as exercise training (Valdez et al., 2010). On the other 
hand, the functions of the NMJ gradually deteriorate during the natural process of aging 
(Courtney and Steinbach, 1981, Balice-Gordon, 1997); moreover, substantial 
reconfiguration of NMJs are elicited in various neuromuscular diseases such as 
amyotrophic lateral sclerosis (ALS) (Schaefer et al., 2005, Dupuis and Loeffler, 2009). 
In these situations, a dominant NMJ organizer like Agrin-Lrp4-MuSK signaling might not 
be optimal, and thus convergence of the fine-tuning signal like NRG1-ErbB becomes 
important to adjust the necessary amount of signaling conveyed into post-synaptic 
muscle cells, or to maintain the dynamics of cellular components. It is therefore of great 
therapeutic interest to characterize the aging- or disease-related alterations of NRG1-
ErbB, and to examine the consequences of manipulating the signaling in neuromuscular 
system diseases.  
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NRG1 isoforms are produced as trans-membrane precursors and undergo 
proteolytic shedding (Falls, 2003, Loeb, 2003, Mei and Xiong, 2008). At chicken NMJs, 
the accumulation of soluble NRG1 at the synaptic basal lamina coincides with the 
concentration of heparin sulfate proteoglycans (HSPGs) (Loeb et al., 1999). Therefore, 
modes of function of NRG1 can be categorized into three types: 1) diffusion as soluble 
factors in the absence of HSPGs; 2) limited diffusion to cell surface by the interaction 
between heparin binding domain (HBD) and HSPGs; and 3) cell-cell contact of 
membrane-bound CRD forms. Before being immobilized by HSPGs, it is reasonable to 
speculate that released forms of NRG1 mainly function at distant areas by diffusion, and 
that subsequent gene expression in the target cells bearing the receptors depends on 
the concentration gradient and the dynamic of the gradient. Similar to some other 
diffusible morphogens, soluble NRG1 proteins are expressed in the early embryo. One 
possibility is that the concentration gradient forms early during embryonic development 
and is retained within the developing limbs to promote myoblast survival and 
differentiation, as during the early stage of NMJ development discussed in Chapter II. Of 
note, however, is the fact that several factors are required for NRG1 expression and 
release, such as retrograde signals from developing muscle target as discussed in 
Chapter III and the activation of PKC-δ signaling within the cell body and axons (Esper 
and Loeb, 2009). It remains unclear at which developmental stage the endogenous 
soluble NRG1 gradient can be achieved. Live examination of the distribution of soluble 
NRG1 from an early developmental stage through the later ones will provide insights to 
this issue. This currently remains a technical challenge, which is shared by all the 
research on soluble growth and differentiation factors.  
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The HBD of most soluble NRG1 is unique with a stand-alone C2 immunoglobulin 
domain that interacts with HSPGs (Ma et al., 2009). HSPGs serve as low-affinity 
targeting system to guide and accumulate the more specific NRG1-ErbB interaction to 
exert the biological functions. Thus, the second mode of NRG1 depends on the tissue-, 
temporal-, and spatial-specific expression pattern of HSPGs. The antagonist used in 
Chapter II is developed by fusing the HBD to extracellular domain of HER4 receptor that 
has been shown to block NRG1-ErbB signaling efficiently both in vivo and in vitro (Ma et 
al., 2009). However, the delivery method of the antagonist to chicken embryo is limited 
as discussed in Chapter II. It is also worthwhile to develop modifications of the 
antagonist with a traceable tag for accurate localization in vivo. Type III NRG1 remains 
membrane-bound after proteolytic cleavage, which makes it ideally positioned to 
function between contacting cells such as axons and myelinating Schwann cells.  
It is interesting that the high concentration of NRG1 activates Erk signaling to 
inhibit Schwann cell myelination, while low concentration switches to the activation of 
PI3K/Akt that promotes myelination, suggesting a dosage-dependent differential 
activation of the downstream signaling pathways in Schwann cells (Syed et al., 2010). It 
would be interesting to examine if the concentration gradient of soluble NRG1 in vivo 
results in similar differential signaling pathway activation. Moreover, the roles of HSPGs 
in the concentration-dependent mode of function can be addressed by using HSPG-
deficient cells or animals. It has been shown that the EGF-like domain of type III NRG1s 
can be liberated further after the first cleavage, resulting in type III NRG1 functioning 
both in a cell-cell contact manner, and in a paracrine manner, though the proportion of 
type III NRG1 undergoing further process remains unknown  (Luo et al., 2011, Fleck et 
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al., 2013). Taken together, how the cooperative dynamics of different modes of function, 
distinct NRG1 isoforms, unique HSPGs in extracellular matrix, and specific cellular 
context account for NRG1 functions in vivo remains unclear and needs more 
investigation in the future. The complexity emphasizes the importance of understanding 
more about the mechanisms by which how isoforms of NRG1 are differentially 
expressed and regulated. 
Human NRG1 is located on chromosome 8p12, spanning about 1.2 Mbp in 
length. It has more than 20 exons and large introns, giving rise to over 30 protein 
isoforms and some long non-coding RNAs, which makes it one of the largest and the 
most complex genes in human genome (Rosenbloom et al., 2013). Both recruitment of 
multiple promoters and regulatory regions and usage of alternative splicing contribute 
the distinct spatial- and temporal-specific expression profiles of different isoforms. It was 
identified as one of the susceptibility genes of schizophrenia in various populations with 
most of the schizophrenia-associated SNPs in 5′ and 3′ flanking regions (Stefansson et 
al., 2002, Stefansson et al., 2003, Li et al., 2004b, Munafo et al., 2006).  Type I NRG1 
was increased in the hippocampus of schizophrenic patients, suggesting that the 
association between NRG1 transcription and schizophrenia is in an isoform-dependent 
fashion (Law et al., 2006). It has been found recently that Wallerian degeneration 
induced de novo type I NRG1 expression in Schwann cells to function as a paracrine 
signal (Stassart et al., 2013). The transcription of type I NRG1 was significantly 
increased by neuronal activity as well (Liu et al., 2011). Type I NRG1 was unregulated 
in both patients and animal models of amyotrophic lateral sclerosis (ALS) (Song et al., 
2012). Outside the nervous system, type I NRG1 was specifically activated to mediate 
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hyperglycemic memory effects in breast cancer (Park et al., 2012). Additionally, work 
from the dissertation showed that neurotrophic factors can induce the transcription of 
type I NRG1 in a temporal-specific manner in mammalian ventral spinal cord cultures, 
whose kinetics closely resembled the ones of some activity-dependent genes (Sato et 
al., 2001). Taken together, it appears that this isoform is the most dynamic and subject 
to transcriptional regulation in various circumstances. Thus it is of great interest to 
understand more about the isoform-specific regulatory machinery. It has been shown 
that there is a putative enhancer region which is responsible for regulating type I NRG1 
expression in breast cancer pathogenesis (Park et al., 2012). It will be interesting to 
examine if the enhancer functions similarly in the nervous system. Moreover, other 
DNase-sensitive clusters are enriched at ~-1k to ~+3k of type I NRG1, which has high 
density of H3K27Ac histone mark, H3K4Me3 histone mark, and transcriptional factor 
binding, all of which suggest that it is a putative regulatory region. As a portion of the 
potential regulatory region, the cis-element of type I tested in Chapter III was found 
essential for BDNF induction of type I transcription. It would be worthwhile to investigate 
if the whole region, especially the region within the first intron, is responsible for the 
binding of regulatory machinery and subsequent transcriptional induction. Furthermore, 
transcriptional factor binding assayed by ENCODE revealed that new transcriptional 
factors such as YY-1 and CTCF are present in the potential regulatory regions, which 
have not been associated with neurotrophic factor signaling before. Whether these 
transcriptional factors are new players in type I NRG1 expression requires further 
investigation. 
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 Unlike in the CNS, damaged neurons in the PNS have an intrinsic ability to 
regenerate. In Wallerian degeneration following peripheral axotomy, axons regenerate 
as long as the neuronal cell body is intact and no underlying disease process is present. 
During peripheral nerve repair, NRG1 is known to be important for Schwann cells to 
alter the transcriptome, de-differentiate, proliferate, and secrete arrays of neurotrophic 
factors (Carroll et al., 1997, Fricker and Bennett, 2011, Fricker et al., 2011). Wallerian 
degeneration induced de novo type I NRG1 expression in Schwann cells themselves 
(Stassart et al., 2013). Highly inducible type I NRG1 from both axons and Schwann cells 
can function in concert to promote Schwann cell differentiation and remyelination. 
Considering that the injury induction of NRG1 is isoform-specific as well, it is of interest 
to understand if the underlying mechanisms are shared by the induction by neurotrophic 
factors. Interestingly, axon-derived NRG1 signaling seemed to inhibit NRG1 expression 
in Schwann cell during normal development (Stassart et al., 2013).  This adds more 
complexity onto the reciprocal signaling between axons and Schwann cells mediated by 
NRG1 and neurotrophic factors. Considering that NRG1-ErbB signaling has been 
implicated in multiple aspects of skeletal muscle development and metabolism (Florini 
et al., 1996, Kim et al., 1999, Suarez et al., 2001, Hippenmeyer et al., 2002, Jacobson 
et al., 2004). It would be of interest to examine if disturbance to the neuromuscular 
system would trigger similar de novo expression in muscle cells in an isoform-
dependent manner, and if axon-derived NRG1 inhibits NRG1 expression in muscles 
during development as well. The potential findings can shed light on therapeutic 
development to a variety of muscular diseases. During development, neurons provide 
NRG1 to support proliferation and differentiation of the glial and target cells; at the same 
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time, NRG1 signal inhibits the production of the same molecule in these cells. Glial and 
target cells secrete neurotrophic factors to promote neuronal survival and axon 
projection, and to stimulate rapid proteolytic processes of NRG1, resulting in the 
formation of a positive feedback loop. When perturbation such as peripheral injury 
occurs, the lack of NRG1 supply from neurons might induce the counterparts to produce 
the growth and differentiation factors, together with the production of the upstream 
regulator such as neurotrophic factors. The network resembles a natural robust system 
which requires more understanding in the future. 
 Both NRG1-ErbB and neurotrophic factors-Trk signaling have been shown to 
play critical roles in various and overlapping aspects in the CNS. Brain-derived 
neurotrophic factor (BDNF) facilitates hippocampus long-term potentiation (LTP), while 
NRG1-ErbB4 regulates the same process negatively (Patterson et al., 1996, Huang et 
al., 2000, Chen et al., 2010). It has been demonstrated that the expression of both 
BDNF and NRG1 isoforms were tightly regulated by neuronal activity (Flavell and 
Greenberg, 2008, Liu et al., 2011). The detailed link between these two signals in the 
central nervous system has not been investigated yet. It is reasonable to speculate that 
similar reciprocal signaling might exist in the CNS as well. Of note is the fact that 
activity-dependent transcription of BDNF has been shown to promote epileptogenesis 
(He et al., 2004), while NRG1 mRNA increases in the hippocampus after a single 
electrical stimulation-induced seizure (Tan et al., 2012). BDNF might contribute to the 
induction of NRG1 signaling, which may serve as an endogenous negative-feedback 
signal to repress the neuronal excitation by activating inhibitory interneurons that bear 
the receptor of ErbB4 (Janssen et al., 2012). This scenario suggests that similar 
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reciprocal signaling might function distinctively depending on the environmental context. 
Recent study has also showed that NRG1 signaling is aberrant in pain after peripheral 
nerve injury and in the motor neuron disease ALS, both of which suggest that NRG1 
signaling is involved in microgliosis (Calvo et al., 2010, Song et al., 2012). In both 
scenarios, damaged neurons are surrounded by pro-inflammatory cytokines and 
chemokines. It would be interesting to examine if there exists reciprocal signaling 
between NRG1 and these soluble factors which can mediate the function of 
inflammatory system. Therefore, fully understanding of the molecular interaction of 
NRG1 and neurotrophic factors, especially in vivo, is important to understand 
development of the nervous system and to develop more effective treatment for 
neurological diseases.  
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Neuromuscular junction (NMJ) development is a multistep process mediated by 
coordinated interactions between nerve terminals, target muscles, and peri-synaptic 
glial cells, and thus requires reciprocal signals derived from every cell type. 
Neuregulin1s (NRG1s) are a family of predominantly neuronal growth and differentiation 
factors that are important for many aspects of nervous system development. In this 
thesis, both the effects of NRG1 on NMJ development and reciprocal effects of 
neurotrophic factors on NRG1 expression were studied as a means to define the 
complex regulatory communication at the NMJ.  Using the chicken embryo as a model, 
methods were developed to study the effects of NRG1 signaling on NMJ development 
in ovo using sequential, quantitative measures of NMJ formation including AChR cluster 
size and density, pre- and post-synaptic apposition, and alignment of peri-synaptic 
Schwann cells.  Over-expression of soluble NRG1 increased AChR cluster density, but 
not size, in the early developmental stage, whereas, blocking NRG1 activity with a 
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targeted antagonist had little effect.  In the middle stage, the NRG1 antagonist led to a 
decrease of AChR cluster size in a temporal-specific and muscle type-dependent 
fashion. The NRG1 antagonist also altered the distribution of synaptic vesicles, 
suggesting NRG1 signaling can modulate the assembly of the pre-synaptic apparatus 
as well. In the late stage, pre- and post-synaptic apposition, and peri-synaptic Schwann 
cell alignment were modestly affected by the antagonist. In motor neurons, NRG1 
expression at the axonal-Schwann cell and neuromuscular junctions is regulated by 
synaptic activity and neurotrophic factors, however, little is known about the 
mechanisms that control NRG1 isoform-specific transcription. Here we show that NRG1 
expression in the chick embryo increases in motor neurons that have extended their 
axons and that limb bud ablation before motor axon outgrowth prevents this induction, 
suggesting a trophic role from the developing limb.  Consistently, NRG1 induction after 
limb bud ablation can be rescued by adding back the neurotrophic factors BDNF and 
GDNF.  Mechanistically, BDNF induces a rapid and transient increase in types I and III 
NRG1 I mRNAs that peak at 4 h in rat embryonic ventral spinal cord cultures.  Blocking 
MAPK or PI3K signaling or blocking transcription with Actinomycin D blocks BDNF 
induced NRG1 gene induction.  BDNF had no effects on mRNA degradation, 
suggesting that transcriptional activation rather than message stability is important.  
Furthermore, BDNF activates a reporter construct that includes 700bp upstream of the 
type I NRG1 start site. Protein synthesis is also required for type I NRG1 mRNA 
transcription as cycloheximide produced a super-induction of type I, but not type III 
NRG1 mRNA, possibly through a mechanism involving sustained activation of MAPK 
and PI3K. These findings suggest that, while not critical for development, NRG1 
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signaling can have important roles in fine-tuning multiple stages of NMJ development 
and that NRG1 isoform expression can be differentially modulated by highly responsive, 
transient transcriptional regulatory mechanisms mediated by neurotrophic factors and 
axon-target interactions. Understanding these mechanisms will be important for 
elucidating the role of NRG1 in both development and in pathological disorders of the 
nervous system. 
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